UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY

United States of America, ex. rel., Eric Johnson

THE FALSE CLAIMS ACT

FIRST AMENDED QUI TAM COMPLAINT PURSUANT TO 31 U.S.C. §3729 AND JURY DEMAND

V.

AmeriHealth Insurance Company of New Jersey; AmeriHealth HMO, Inc. Independence Holdings, Inc.

DOCKET # 1:17-CV-11646-RBK-JS

Defendants

FIRST AMENDED QUI TAM COMPLAINT PURSUANT TO THE FALSE CLAIMS ACT, 31 U.S.C. §3729 ET SEQ.

TABLE OF CONTENTS

I. Ba	ckground and Introduction
II. Th	e Parties
	A. Plaintiff/Relator
	B. Defendants
	1. AmeriHealth Insurance Company of New Jersey 6
	2. AmeriHealth HMO, Inc
	3. Independence Holdings, Inc 8
	C. The United States 8
III. Ju	urisdiction
	enue 9
	e Patient Protection and Affordable Care Act 9
	A. Overview 9
	B. The ACA Minimum Cost Sharing Threshold 12
	C. The Insurance Exchanges
	D. The Subsidy System
	1. Advanced Premium Tax Credits (APTC) 16
	2. Cost Sharing Reductions (CSR)
	3. Subsidy Based on The Federal Poverty Level 18
	4. The "Silver Plan" and The Actual Subsidy 20
	5. Insurers Receive Advance Payments of Cost-Sharing
	Reduction Subsidies
	6. ACA's Reinsurance Program For High Cost Enrollees 23
	E. QHP Issuer Required Certification
	QHP Certification Process
	The New Jersey Minimum Cost Sharing Threshold
	The Defendants Qualified Health Plans in New Jersey 29
	Defendant's Fraudulent Cost Sharing Violates New Jersey Standards
	A. Defendants Violation of N.J.A.C.11:22-5.5(a)11 Relating to
	Physical Therapy, Speech Therapy, Occupational Therapy
	and Chiropractic Services

B. Defendants Were Aware of The Violations Since 2011 34
C. Certifications in QHP Applications by Defendants to CMS Were False
D. The 2014 Review
E. The 2015 Review 41
X. Defendant's Violation of the False Claims Act
A. The False Claims Act
1. The FCA And False Certification 42
2. AmeriHealth's Failure to Comply With N.J.A.C.11:22-5.5(a)(11) Was Material to the Government's Payment Decision
3. Factors to Consider In Natural Tendency Test 46
4. Damages Under the False Claims Act 54
B. Defendant's Implied Certification
C. Defendant's Express Certification
XI. Causes of Action 56
A. Count One 31 U.S.C. § 3729(a)(1)(A)
XII. Relief Requested 58

I. BACKGROUND AND INTRODUCTION

- 1. Plaintiff/Relator Eric Johnson ("Relator") hereby files this First
 Amended Complaint¹ (herein "FAC") pursuant to The False Claims Act, Section 31
 U.S.C. Title 3729 and 3730, under which a civil action may be brought for violations of 31 U.S.C. Section 3729 ("FCA") regarding false claims on behalf of the United
 States Government.
- 2. The purpose of this Amended Complaint is to, inter alia, incorporate certain allegations and evidence voluntarily submitted to the United States by Relator in supplemental disclosures since the filing of the original Complaint. The facts and allegations set forth in respective footnotes herein are intended be incorporated in the relevant paragraphs as if more fully forth at length therein.
- 3. Defendants AmeriHealth Insurance Company of New Jersey, a New Jersey licensed insurer, and AmeriHealth HMO, Inc., a Pennsylvania corporation (both subsidiaries of Independence Blue Cross's Holding Company) are licensed to sell health insurance in New Jersey. After receiving approval from the State of New Jersey to qualify and certify several of it's proposed health insurance plans² (collectively, the "Plans"), both applied for approval from the Center for Medicare and Medicare Services (CMS) for the Plans to be certified as Federal Qualified

 $^{^1}$ The Original Complaint was filed under seal on November 17,2017 and was served on the United States on November 20, 2017.

 $^{^2}$ Plans are those submitted and are described herein at ¶ 75.

Health Plans³ (QHP) and offered through a Federal Facilitated Exchange (FFE) under the provisions of the Patient Protection and Affordable Care Act (ACA).

4. In order to qualify as a QHP, and therefore be eligible for subsidies and reimbursements pursuant to the ACA, applicants such as Defendants herein are required to certify in their application to CMS that its proposed health insurance plans have been approved by the relevant State Agency. In addition, the ACA requires that plans must meet both applicable State insurance laws⁴ and regulations and all Federal QHP requirements and certification standards. This includes the New Jersey State regulatory requirement that the network copayments for certain services, such as physical therapy, speech therapy, occupational therapy and chiropractic, be no more than 50 percent or more of the aggregate risk for the service or supply to which the copayment is applied. In other words, the Insurer must be responsible for at least fifty per cent (50%) of the cost.

³ Qualified health plan or QHP means a health plan that has in effect a certification that it meets the standards described 45 C.F.R part 156 issued or recognized by each Exchange through which such plan is offered in accordance with the process described in 45 C.F.R. part 155.

⁴ 45 C.F.R. 156.200(d) states: . . . (d) State requirements. A QHP issuer certified by an Exchange <u>must adhere to the requirements of this subpart and any provisions imposed by the Exchange, or a State in connection with its Exchange, that are conditions of participation or certification with respect to each of its QHPs [emphasis added]</u>

- 5. Defendants knew that the New Jersey State regulation⁵ mandating that the network co-pay requirement be no more than 50 percent or more of the aggregate risk for the service or supply was material to obtaining QHP status and eligibility to submit claims for and receive ACA subsidies and payments. In this action, Relator alleges that Defendants knowingly violated the False Claims Act and committed fraud (i) knowingly submitting and certifying false claim information and cost data to the New Jersey Department of Banking and Insurance (DOBI) to order receive approval for its Plans as qualified health plans or QHP status, (ii) by charging co-pay amounts in excess of the statutory maximum (\$50 and above) to its members for chiropractic, physical therapy, occupational therapy, and speech therapy services for certain Qualified Health Plan in contract years 2014 and 2015 that exceeded 50% of its average cost for these services and (iii) reporting and certifying the same false data to CMS during the reconciliation as they did during the initial qualification and certification of their Plans.
- 6. As an Insurer certified by CMS, both AmeriHealth Insurance Company of New Jersey and AmeriHealth HMO, Inc. through their QHPs received significant subsidies from the Federal Government to reduce the enrollees' monthly premium payments for insurance plans, cost share reduction subsidies to offset copays,

⁵ N.J.A.C. 11:22-5.5 Network Co-payment states: (a) Network copayments in health benefit plans and stand-alone prescription drug plans may not exceed the following . . . (11). For any other services and supplies, the copayment is to be determined so that the carrier insures 50 percent or more of the aggregate risk for the service or supply to which the copayment is applied. (This section would be the operative requirement involving the services at issue here, i.e., physical therapy, occupational therapy, speech therapy and chiropractic services.)

deductible, and coinsurance to low income members and reinsurance to offset high cost members. During 2014 and 2015, these subsidies totaled over 133 million dollars. [See Exhibit F]

- AmeriHealth HMO, Inc. knowingly and falsely certified that they were in compliance with New Jersey's network co-pay regulation N.J.A.C. 11:22–5.5(a)(11). In contract year 2014, which submission was made in 2013, Defendants, in reckless disregard of the DOBI, QHP and CMS regulations and requirements, did not even test their Plans for compliance. In contract year 2015, Defendants had actual knowledge that the Plans were not compliant in that they knew their combined average cost was \$93.69 and they were charging copays of \$50, \$60 and \$75 dollars (putting them all above the 50% threshold). Specifically, for 2014, the copay amounts in their Plans of \$50, \$60 and \$75 were in violation. For 2015, the copays of \$60 and \$75 in their Plans were in violation. Notwithstanding the foregoing, they continued to submit and certify claims to CMS for subsidies and or payments knowing they were not in compliance.
- 8. Had the New Jersey Department of Banking and Insurance (DOBI) known that the Defendants submitted untested and false data in order to "show" compliance it would not have certified or approved Defendants health insurance Plans as qualified health plans.
- 9. Had the United States and the Department of Health and Human Services ("HHS"), and its Centers for Medicare & Medicaid Services ("CMS"), who

are the administrators and the Government payers of the ACA known that the Defendants fraudulently obtained QHP certification from New Jersey DOBI for its Plans, it would not, and as a matter of law, could not, pay Defendants subsidies or reimbursements for claims submitted by them.

10. This action is brought under the FCA against Defendants for knowingly presenting or causing to be presented to the United States (i) false or fraudulent claim for payment, and (ii) making, using, or causing to be used or made, a false record or statement to get a false or fraudulent claim paid.

II. THE PARTIES

A. Plaintiff/Relator

- 11. Relator Eric Durand Johnson resides at 1237 E. Durham Street,
 Philadelphia, PA., 19150. He is currently employed at Independence Blue Cross
 (IBC) as an Actuarial Analyst III within the Actuarial Department.
- 12. Relator is the original source of the allegations in this FAC. The allegations are not based upon publicly disclosed information. Prior to filing the original Complaint and this FAC, Relator has provided the United States with Disclosure Statements as part of Relator's obligation to provide the government with material information prior to filing a Complaint in accordance with 31 U.S.C. § 3730(b)(2).
- 13. Since 2011, Relator's duties include performing monthly cost share reduction estimates for the ACA and assisted in creating annual filings to CMS, preparing simulation results for the ACA risk adjustment program, and setting

monthly reserve estimates for prescription drug rebates. Relator is not in a managerial function and has no decision-making abilities at IBC-AmeriHealth. Beginning in 2005 through until 2006, Relator worked at UHG - AmeriChoice in Philadelphia, PA as a Sr. Financial Analyst, assisted in preparing rate filings for both Medicare and Medicaid plans (including data analysis for unit cost and utilization trends) and developing database utility (in MS Access) used to compile and analyze CMS premium payments for reconciliation and reserve estimates.

Analyst. His primary duties included designing CMS payment software (in MS Access / SQL Server) to reconcile and track CMS member risk score, payment, and eligibility status for accuracy based on retroactive submissions. This included designing automated reporting (paid / incurred basis) process to show changes in incurred risk scores (Part C and D) based on CMS restatements; CMS risk score and payment summaries by Contract, PBP, County, and Eligibility status; CMS capitation triangles to monitor the amount of retroactivity by month; and the preparation of Medicare BID filings.

B. Defendants.

- 1. AmeriHealth Insurance Company of New Jersey
- 15. Defendant AmeriHealth Insurance Company of New Jersey, is a stock health insurance corporation⁶ organized under the laws of the State of New Jersey

⁶ Independence Insurance Benefits Company was incorporated under the laws of New Jersey on April 4, 1994. On March 10, 1995 the name was changed from Independence Insurance Benefits

("AMNJ"). It's principal office is located at 1901 Market Street, Philadelphia, PA., 19103. In New Jersey, AMNJ sold individual, small group and large group health insurance plans on and off the federal exchanges. In the individual market in New Jersey, AMNJ had 79,447 enrollees in 2014 and 38,354 enrollees in 2015.

- 2. AmeriHealth HMO, Inc⁷.
- 16. AmeriHealth HMO, Inc. (AMHMO) is a Pennsylvania corporation, authorized and formed to provide health care services to people in New Jersey, Delaware, and Pennsylvania.
- 17. AMHMO offers an HMO, a preferred provider organization plan, traditional coverage, for the senior market and health insurance coverage to employers and individuals. AmeriHealth HMO offers one of the largest provider networks with nearly 9,500 primary care physicians, over 24,000 specialists, and

Company to AmeriHealth Insurance Company of New Jersey (AMNJ). AMNJ was authorized to transact business pursuant to N.J.S.A. 17B:18-42 on June 6, 1995. Thereafter AMNJ became a wholly owned subsidiary of Independence Blue Cross. Through subsequent reorganizations and restructuring that occurred, AmeriHealth Insurance Company of New Jersey is now wholly owned by Independent Holding, Inc., the corporate holding company for many Independence Blue Cross affiliates.

⁷ Greater Delaware Valley Healthcare was an HMO incorporated under the laws of Pennsylvania on February 18, 1976. On December 23, 1986 all issued and outstanding stock of the Greater Delaware Valley Healthcare was acquired by AmeriHealth Integrated Benefits, Inc., a wholly-owned subsidiary of AmeriHealth, Inc. which in turn was a wholly-owned subsidiary of Independence Blue Cross (hereinafter referred to as "IBC"). The name was changed to Delaware Valley HMO, Inc. (AMHMO) on July 11, 1988 and the name was changed again to AmeriHealth HMO, Inc. on July 1, 1995. AMHMO became authorized to operate in New Jersey pursuant to N.J.S.A. 26:2J-1 et seq., (the Health Maintenance Organization Act) on May 9, 1995. Through a series of corporate reorganizations and restructuring that took place in 2013, AMHMO is now a wholly-owned subsidiary of Independence Holdings, Inc. the corporate holding company for many Independence Blue Cross affiliates.

over 230 hospitals in New Jersey and Delaware, and Southeastern Pennsylvania. It's principal office is located at 1901 Market Street, Philadelphia, PA., 19103. In the individual market in New Jersey, AMHMO had 25,373 enrollees in 2014 and 13,003 enrollees in 2015.

- 3. Independence Holdings, Inc.,
- 18. Independence Holdings, Inc., and its affiliated entities (hereinafter trading as Independence Blue Cross or Independence Blue Cross Family of Companies ("IBC") is the sole shareholder and holding company for AMNJ and AMHMO. IBC provides shared services and support to AMNJ and AMHMO in connection with management. It's principal office is located at 1901 Market Street, Philadelphia, PA., 19103. Collectively, AMNJ, AMHMO and IBC are hereinafter referred to as Defendants.
 - C. The United States
- 19. The United States of America is a real party in interest pursuant to the FCA, and specifically on behalf of several United States' agencies: the Department of Health and Human Services ("HHS"); its Centers for Medicare & Medicaid Services ("CMS"), as CMS administers the Affordable Care Act which the Defendants' unlawful and fraudulent actions harmed.

III. JURISDICTION

20. This action arises under the FCA, 31 U.S.C. §§3729 et seq., and the Court has subject matter jurisdiction over this action pursuant to 28 U.S.C. §§1331 and 1345.

IV. VENUE

21. Venue in this district is proper pursuant to 31 U.S.C. §3732(a) and 28 U.S.C. §1391(b) and (c) since one or more of the Defendants transact business in this district and/or one or more of the acts at issue occurred in this district.

V. THE PATIENT PROTECTION AND AFFORDABLE CARE ACT

A. Overview

- 22. The Patient Protection and Affordable Care Act (Pub. L. 111-148) was enacted on March 23, 2010. The Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152), which amended and revised several provisions of the Patient Protection and Affordable Care Act, was enacted on March 30, 2010. These two statutes are collectively referred to as the "Affordable Care Act" or "ACA."
- 23. The ACA allows each State the opportunity to establish or participate in an Affordable Insurance Exchange⁸ (the "Exchange(s)"), which is designed to help

⁸ Pursuant to 45 C.F.R. 155.20, Exchange means a governmental agency or non-profit entity that meets the standards described 45 C.F.R part 156 and makes QHPs available to qualified individuals and/or qualified employers. Unless otherwise identified, this term includes an Exchange serving the individual market for qualified individuals regardless of whether the Exchange is established and operated by a State (including a regional Exchange or subsidiary Exchange) or by HHS

individuals and small employers purchase affordable health insurance coverage. Exchanges (see below) are intended to allow individuals and eligible employers to compare and select from qualified health plans (QHPs) that meet all Federal requirements of the ACA as well as all related minium insurance requirements of the respective States in which the QHP is offered.

- 24. The ACA requires non-grand fathered health plans in the individual and small group markets to cover essential health benefits (EHB), which include items and services in the following ten benefit categories: (1) ambulatory patient services; (2) emergency services; (3) hospitalization; (4) maternity and newborn care; (5) mental health and substance use disorder services including behavioral health treatment; (6) prescription drugs; (7) rehabilitative and habilitative services and devices; (8) laboratory services; (9) preventive and wellness services and chronic disease management; and (10) pediatric services, including oral and vision care.
- 25. Health and Human Services (HHS) regulations implementing the ACA define EHB based on state-specific EHB benchmark plans. 45 C.F.R. 156.100. The Benchmark Plan selected by New Jersey for 2014 and 2015 is the Horizon HMO Access HSA Compatible. Habilitation services (which encompasses physical therapy, occupational therapy and speech therapy) are included in this plan. A copy of the full NJ Benchmark Plan is attached hereto as Exhibit A.

⁹ Health care services that help you keep, get back, or improve skills and functioning for daily living that have been lost or impaired because you were sick, hurt, or disabled. These services may include physical and occupational therapy, speech-language pathology, and psychiatric rehabilitation services in a variety of inpatient and/or outpatient settings.

- 26. The highlights of the ACA include the following provisions:
- Requires most U.S. citizens and legal residents to have health insurance¹⁰. The ACA creates Exchanges through which individuals can purchase coverage, with premium and cost sharing credits available to individuals/families with income between 133-400% of the federal poverty level and creates separate Exchanges through which small businesses can purchase coverage¹¹.
 - Expands Medicaid to 133% of the federal poverty level.
- Provides refundable and advanceable premium credits to eligible individuals and families with incomes between 100-400% of the Federal Poverty Level (FPL) to purchase insurance through the Exchanges. The premium credits are tied or "benchmarked" to the "second lowest cost silver plan" in the State and will be set on a sliding scale such that the premium contributions are limited to a percentage of income. Provisions related to the premium and cost-sharing subsidies went into effect January 1, 2014.

¹⁰ For plan years through 2018, if an individual could afford health insurance but choose not to buy it, payment of a fee called the individual Shared Responsibility Payment was required. (The fee is sometimes called the "penalty," "fine," or "individual mandate.") Starting with the 2019 plan year, the Shared Responsibility Payment no longer applies.

¹¹ Limit availability of premium credits and cost-sharing subsidies through the Exchanges to U.S. citizens and legal immigrants who meet income limits. Employees who are offered coverage by an employer are not eligible for premium credits unless the employer plan does not have an actuarial value of at least 60% or if the employee share of the premium exceeds 9.5% of income. Legal immigrants who are barred from enrolling in Medicaid during their first five years in the U.S. will be eligible for premium credits.

27. Section 1313(a)(6)(A)¹² of the ACA specifies that payments made by, through, or in connection with an Exchange, are subject to the False Claims Act (31 U.S.C. §3729, et seq.) if those payments include any Federal funds. It further states that compliance with this requirement shall be a material condition of an issuer's entitlement to receive payments, including payments of premium tax credits and cost-sharing reductions, through the Exchange. Specifically, section 1313 of the Affordable Care Act, entitled FINANCIAL INTEGRITY, provides in subsection (a)(6), "Accounting for Expenditures," the following:

. . **.**

- (6) APPLICATION OF THE FALSE CLAIMS ACT-
- (A) IN GENERAL- <u>Payments made by, through, or in connection with an Exchange</u> are subject to the False Claims Act (31 U.S.C. 3729 et seq.) if those payments include any Federal funds. Compliance with the requirements of this Act concerning eligibility for a health insurance issuer to participate in the Exchange <u>shall be a material condition of an issuer's entitlement to receive payments</u>, including payments of premium tax credits and cost-sharing reductions, through the Exchange.[emphasis added]
- B. The ACA Minimum Cost Sharing Threshold
- 28. The ACA establishes various "metal" tiers (i.e., bronze, silver, gold and platinum) of health insurance coverage. These tiers are used for three primary purposes as follows:

¹² 42 U.S.C. 18033

- To set the minimum amount of coverage many people must have to satisfy the requirement that they be insured or pay a federal tax penalty beginning in 2014.
- To establish standardized levels of insurance individuals and small businesses can buy in health insurance purchasing Exchanges or in the outside market; and
- As benchmarks for premium and cost-sharing subsidies provided to lower and middle income people buying their own insurance in Exchanges.
- These requirements apply to all tiers of health insurance coverage, meaning that differences in the levels of coverage will reflect only variation in cost-sharing, not differences in the underlying benefits. However, the levels of coverage in the ACA are not defined using specific deductibles, copays, and coinsurance. Rather, they are specified using the concept of an "actuarial value" (AV). For example, a plan with an actuarial value of 70% (referred to as a "silver" plan in the ACA) means that for a standard population, the plan will pay 70% of their health care expenses, while the enrollees themselves will pay 30% through some combination of deductibles, copays, and coinsurance.
- 30. The higher the actuarial value, the less patient cost-sharing the plan will have on average. The percentage a plan pays for any given enrollee will generally be different from the actuarial value, depending upon the health care services used and the total cost of those services. The details of the patient cost sharing vary from plan to plan. The ACA specifies that beginning in 2014 insurance

newly sold to individuals and small businesses in an Exchange or otherwise must be at one of four actuarial value levels: 60% (a bronze plan), 70% (a sliver plan), 80% (a gold plan), and 90% (a platinum plan).

- C. The Insurance Exchanges
- 31. Beginning in 2014, individuals and small businesses were able to purchase private health insurance through competitive marketplaces called Affordable Insurance Exchanges, "Exchanges," or "Marketplaces." Individuals, who qualify, and who enroll in a QHP through Exchanges receive financial assistance in the form of "premium tax credits" and "cost sharing reductions" that are intended to make health insurance more affordable and financial assistance to cover some or all cost sharing for essential health benefits.
- 32. Coverage through the Exchange began in every State on January 1, 2014, with enrollment beginning October 1, 2013. Recognizing that not all States would elect to establish a State-based Exchange by this statutory deadline, the Affordable Care Act directed the Secretary of HHS to establish and operate a Federally Facilitated Exchange (FFE) in any State that did not elect to do so, or will not have an operable Exchange for the 2014 coverage year, as determined by January 1, 2014. New Jersey falls into this category.
- 33. States had the option under the ACA to (i) establish it's own Exchange,(ii) enter into a Partnership with an Federally-Facilitated Exchange (FFE) in any

State where a State-based Exchange is not operating or (iii) operate through a Federally Facilitated Exchange or marketplace.

- 34. Under a State Partnership model, a State may administer plan management functions, in-person consumer assistance functions, or both. In non-Partnership FFE States, FFEs will perform these functions. 77 Fed. Reg. 18310 (March 27, 2012); 45 C.F.R. parts 155, 156 and 157.
- 35. New Jersey has adopted to operate through a FFE or Federally Facilitated Marketplace.
- 36. State Exchanges and Federal Exchanges are equivalent. The United States Supreme Court has found that there is no difference in a FFE and State created Exchange. They must meet the same requirements, perform the same functions, and serve the same purposes. Although State and Federal Exchanges are established by different sovereigns, Sections 18031 and 18041 of the ACA do not state that they differ in any meaningful way. King v. Burwell, 135 S.Ct. 2480 (2015)
 - D. The Subsidy System
- 37. Insurers who offer QHPs for individuals qualify for several government subsidies including the following:
- Advanced Premium Tax Credits (APTC) to reduce the enrollees'
 monthly premium payments for insurance plans purchased through the Exchange

or Marketplace based on the individual or families income in relation to the Federal Poverty Level (FPL).

- Cost Share Reduction subsidies to offer co-pays, deductible, and coinsurance at a reduction to low income members based on the individual or families income in relation to the FPL.
 - Reinsurance to offset high cost members.

These subsidies, discussed and described herein form the basis for the false claims submitted and received by Defendants.

- 38. The amount of two of these subsidies directly involve the income levels of individuals or families with low to moderate income. In order to ensure that health coverage is available for individuals/families with income between 133-400% of the Federal Poverty Level, coverage can be purchased through the Exchanges with "subsidies" to assist with paying health insurance premiums (through "Advance Premium Tax Credits") and assistance with payment of co-pays, deductibles, or co-insurance (through "Cost Sharing Reductions").
 - 1. Advanced Premium Tax Credits (APTC)
- 39. The advance premium tax credit (APTC) reduces the enrollees' monthly premium payments for insurance plans purchased through the Exchange or Marketplace. Health insurance plans offered through the Marketplace are standardized into four "metal" levels of coverage: bronze, silver, gold, and platinum.

- 40. The ACA creates a subsidy system for low and some middle income families to help in the purchase of insurance on the insurance exchanges. The ACA sets a cap on the amount of insurance premium that individuals and families will have to pay, based on the second cheapest Silver plan and that person/family's income in relation to the Federal Poverty Level (FPL)
- 41. Each "metal" plan will have subsets or "variants" to which enrollees will be assigned, which assignment is based on the level of income of the enrollee. The variant plans for each "metal" category are identical to the "master plan" in term of benefits. The only distinction being the level of assistance that the enrollee is receiving. As example, the benefits are the same in all Silver plans, master and variants, except for the amount of CSR (subsidy) that is being provided.
- 42. Using information available at the time of enrollment, the Exchange determines whether the individual meets the income and other requirements for APTC payments and the amount of the payments that can be used to pay premiums. APTC, once determined, are essentially assigned to the Insurer selected on the Exchange and are made periodically to the issuer of the QHP in which the individual enrolls through a subsidy system. See sections 1401, 1411, and 1412 of the Affordable Care Act and 45 CFR part 155 subpart D.
 - 2. Cost Sharing Reductions (CSR)
- 43. The ACA also requires issuers of QHPs to provide "reduced cost sharing" for essential health benefits (EHB) to eligible Marketplace enrollees. Cost

sharing is defined at 45 C.F.R. 155.20 as expenses on behalf of an enrollee for essential health benefits, including deductibles, co-pays, and coinsurance.

- 44. Cost sharing does not include premiums, balance billing for out-of-network services, or out-of-pocket expenses for non-covered services. A cost-sharing reduction (CSR) plan is a variation of a standard plan that offers identical benefits and providers as the standard plan, except that the enrollee's out-of-pocket costs for essential health benefits are reduced depending on the consumer's eligibility. Reduced cost sharing must be available to eligible enrollees who are enrolled in a silver level plan through the Marketplace.
- 45. As set forth at 45 CFR 156.410, the QHP issuer must ensure any individual enrolled through the Marketplace who is eligible for cost-sharing reductions (CSR) pays only the cost sharing required for the applicable covered service under the plan variation, and, in the case of improper assignment to a plan variation or improper cost sharing, the issuer must correct the plan variation assignment or refund the consumer.
 - 3. Subsidy Based on The Federal Poverty Level
- 46. Each year the Federal Government benchmarks the Federal Poverty Level (FLP) at a certain income. Eligibility for some government services and benefits depends on how much income is above or below this number.

Household	Feder	al Poverty Level	
$\underline{\mathrm{Size}^{^{13}}}$	<u> 2013 - 2014</u>	<u> 2014 - 2015</u>	2015 - 2016
1	\$11,490	11,670	11,770
2	\$15,510	15,730	15,930
3	\$19,530	19,790	20,090
4	\$23,550	23,850	24,250

- 47. The FPL impacts insurance spending by capping the amount required to be spent. To illustrate, for a single individual with an income of \$28,725, the applicable FPL would be \$11,490 in 2014 and their income would be 250% of that amount. Under the law this would cap their yearly premium for the Silver Plan at 8.05% of their annual income, i.e., \$2,313 annually or about \$193 monthly. The remainder of the premium would be paid through the subsidies as described herein.
- 48. For a family of 4 earning \$47,100 they would have an income of 200% FPL (\$23,550) and under the ACA would have premiums capped at 6.3% of their annual income: \$2967.30 or \$246.27 monthly.

Income as % of FPL	Cap % (Lower End)	Cap % (Higher End)
Up to 133%	2.0%	2.0%
133% - 150%	3.0%	4.0%

 $^{^{13}}$ Additional family members past 4, increase the federal poverty level number by an additional $4{,}060$

150% - 200%	4.0%	6.3%
200% - 250%	6.3%	8.05%
250% - 300%	8.05%	9.5%
300% - 400%	9.5%	9.5%

- 4. The "Silver Plan" and The Actual Subsidy
- 49. The subsidy is based on the "Second Cheapest Silver Plan" authorized by each State. Under the ACA, insurers that sell plans on the exchanges must categorize each plan under one of 4 "metal tiers" based upon how much of the policyholders total health care costs the plan will cover.
- 50. The preceding premium cap calculations are used to determine how much a family would have to pay themselves for the "second cheapest Silver plan" available to them. Because insurance costs vary from State to State, the government then subsidizes any amount that the cost of that Silver Plan exceeds the premium cap. If the silver plan costs more than the premium cap would be, the "subsidy" makes up the difference. As an example, for the single person, if the benchmark silver plan cost \$300 a month in premiums, the person would still only be responsible for \$193 dollars a month and receive a subsidy for the difference of \$107 dollars. The consumer could even opt to buy a cheaper Bronze plan or a more expensive option, and apply the same \$107 dollar subsidy. (Note: If the cheaper plan actually costs less than \$107 dollars a month, they would not receive the difference and lose the remainder of the subsidy received

- 5. Insurers Receive Advance Payments of Cost-Sharing Reduction Subsidies
- 51. QHP issuers are required to notify the Secretary of HHS of cost-sharing reductions provided on behalf of eligible enrollees. In addition, periodic and timely payments equal to the value of those reductions are required to be made to the issuers. These payments are made in advance.
- 52. Under the ACA and implementing regulations, CMS reconciles the cost-sharing reduction portion of advance payment amounts by comparing what the enrollee in a cost-sharing reduction plan variation paid in cost sharing to what the enrollee would have paid if enrolled in a standard plan.
- 53. In order to facilitate reconciliation of advance payments of cost-sharing reductions to reflect the amount provided to enrollees in cost-sharing reduction variation plans, issuers must report the amount they paid for each eligible medical claim, the amount enrollees paid for the claims, and the amount of cost sharing that would have been paid for the same services under the corresponding standard plan. CMS uses this information to ensure payments reflect the cost-sharing amounts provided for each policy in a plan variation. Defendants reported the same false data to CMS during the reconciliation as they did during the initial qualification and certification of their Plans.
- 54. As set forth at 45 CFR 156.410(d)(3), issuers are not reimbursed for any cost-sharing reductions provided to enrollees who were erroneously assigned to

a plan variation more generous than the one for which they are eligible. Any cost-sharing reductions, to the extent thereby or otherwise erroneously provided (such as cost-sharing reductions for non-EHB or non-covered services or cost-sharing reductions provided after a policy has been terminated), must be excluded from the reconciliation process. The only exception is provided under 45 CFR 156.430(f)(3), which permits issuers to seek reimbursement for cost-sharing reductions provided during a retroactive termination in which failure to terminate was not the fault of the QHP issuer, for example, when the QHP issuer receives a late termination notice from the Exchange.

- 55. CMS requires issuers to adjudicate and re-adjudicate cost-sharing reductions separately from reconciliation of state advance payments for state subsidies that further reduce cost sharing for eligible enrollees in cost-sharing reduction plans, to ensure correct calculation of accumulators and re-adjudication of federal cost-sharing reductions provided.
- 56. In the case of claims with coordinated benefits (COB), issuers must apply the COB amounts consistently to standard plans and plan variations when reporting total allowed costs. Issuers with little or no enrollment in a plan or enrollees with few claims for which cost-sharing reductions were provided may elect to reimburse CMS the full advance payment amount for those plans or policies rather than re-adjudicate such claims. Issuers that wish to return advance

payments for a policy that has been terminated must be excluded from the reconciliation process.

- 6. ACA's Reinsurance Program For High Cost Enrollees
- 57. The goal of the ACA's reinsurance program¹⁴ was to stabilize individual market premiums due to the new reform of "guaranteed issue" for QHPs. The program was in place from 2014 through 2016. The program transfers funds to individual market insurance plans with higher-cost enrollees in order to reduce the incentive for insurers to charge higher premiums due to new market reforms that guarantee the availability of coverage regardless of health status. Reinsurance payments are based on actual costs. Under reinsurance, some plans may receive payments for high-cost/high-risk enrollees, and still be eligible for payment for those enrollees under risk adjustment.
- 58. The ACA set national levels for reinsurance funds at \$10 billion in 2014, \$6 billion in 2015, and \$4 billion in 2016. Based on estimates of the number of enrollees, HHS set a uniform reinsurance contribution rate of \$63 per person in 2014, \$44 per person in 2015, and \$27 per person in 2016.

¹⁴Reinsurance differs from risk adjustment in that reinsurance is meant to stabilize premiums by reducing the incentive for insurers to charge higher premiums due to concerns about higher-risk people enrolling early in the program, whereas risk adjustment is meant to stabilize premiums by mitigating the effects of risk selection across plans. Reinsurance payments are only made to individual market plans that are subject to new market rules (e.g., guarantee risk adjustment payments are based on expected costs. ed issue), whereas risk adjustment payments are made to both individual and small group plans.

- 59. Eligible QHPs received reinsurance payments when the plan's cost for an enrollee crosses a certain threshold, called an "attachment point." HHS sets the attachment point (a dollar amount of insurer costs, above which the insurer is eligible for reinsurance payments) at \$45,000 in 2014 and 2015. Because of the smaller reinsurance payments pool for 2016, HHS raised the attachment point to \$90,000 for the 2016 benefit year. HHS also set a reinsurance cap (a dollar-amount threshold, above which the insurer is no longer eligible for reinsurance) at \$250,000 in 2014, 2015, and 2016
 - E. QHP Issuer Required Certifications
- 60. In order to participate in an Exchange, Defendants must have in effect a certification issued or recognized by the Exchange to demonstrate that each health plan it offers in the Exchange is a QHP. 45 C.F.R. §156.200(a).
- 61. Defendants, as the QHP issuer must be in compliance of all QHP Issuer Minimum Certification Standards set forth in 45 C.F.R. 156.200(b) with respect to each of its QHPs on an ongoing basis. The Certification Standards, include, inter alia, adherence to the State requirements and any provisions imposed by a State's QHPs. 45 C.F.R. 156.200(d) as follows:

State requirements. A QHP issuer certified by an Exchange <u>must adhere to the requirements of this subpart and any provisions imposed by the Exchange, or a State in connection with its Exchange, that are conditions of participation or certification with respect to each of its QHPs [emphasis added].</u>

62. Each request for payment of "advance tax credits" (or subsidy) for qualified enrollees in one of its QHPs, constitute a certification of compliance by Defendants. This certification, by the express terms of the ACA is material to the payment of the subsidy [see ACA Section 1313(a)(6)(A)¹⁵]

VI. QHP CERTIFICATION PROCESS

- 63. Section 1311(d)(4)(A) of the Affordable Care Act directs that each Exchange must implement procedures for the certification, re-certification, and decertification of health plans as QHPs, consistent with guidelines developed by the Secretary.
- 65. In accordance with 45 C.F.R. part 155 subpart K, CMS will review and approve or deny applications from issuers that are applying to offer QHPs in a FFE. Application for certification as a QHP in a FFE for the 2014 plan year where submitted electronically to CMS through it's Health Insurer Oversight System (HIOS). Upon acceptance, each plan is issued a HIOS identification number.
- 66. Insurers seeking certification, such as defendants herein, were required to access the QHP Application in HIOS and submit all information necessary for certification of health plans as QHPs. The QHP Application includes both issuer-level and plan-level benefit and rate data and information, largely through standardized data templates.

¹⁵ 42 U.S.C. 18033

- 67. Insurers seeking certification, such as Defendants herein, also attest and certify as part of the Application, to their adherence to all of the regulations set forth in 45 C.F.R. parts 155 and 156, which specifically includes State insurance requirements and other programmatic requirements necessary for the operational success of an Exchange, and are required to provide any requested supporting documentation. Defendants certification with respect to compliance with New Jersey State requirements was material and knowingly false.
- 68. Defendants, as an issuer who offered QHPs through an FFE must meet both applicable State laws and requirements and QHP certification standards. As set forth above, this includes, inter alia, adherence to the State requirements referenced in 45 C.F.R. 156.200(d)¹⁸ and any provisions imposed by a State's QHPs, including N.J.A.C. 11:22–5.5 Network Co-Payment. As a result, Defendants, at the time of their application for QHP status, falsely and expressly certified compliance with N.J.A.C. 11:22–5.5(a)(11).
- 69. An FFE's role and authority are limited to the certification and management of participating QHPs, and do not extend beyond the Exchange or

¹⁶ See .45 C.F.R. 156.200(d) states: . . . (d) State requirements. A QHP issuer certified by an Exchange must adhere to the requirements of this subpart and any provisions imposed by the Exchange, or a State in connection with its Exchange, that are conditions of participation or certification with respect to each of its QHPs

¹⁷ See HHS Affordable Exchange Guidance dated April 5, 2013 from Center for Consumer Information and Insurance Oversight, Center for Medicare & Medical Services, Chapter 2, Section 1(i), page 20; at https://www.cms.gov/CCIIO/Resources/Regulations-and-Guidance/Downloads/2014_letter_to_issuers_04052013.pdf

¹⁸ See n. 15 above regarding 45 C.F.R. 156,200(d).

affect otherwise applicable State law governing which health insurance products may be sold in the individual and small group markets. Several QHP certification standards rely on reviews that State departments of insurance (DOI) do not currently conduct. The New Jersey Department of Banking and Insurance (DOBI) is the relevant governing and enforcement agency for New Jersey for certification, compliance and enforcement of New Jersey State requirements as it relates to QHPs.

- 70. CMS evaluates each potential QHP against all applicable certification standards, either by confirming the outcome of a State's review (as in the case of licensure) or by performing the review. In the case of New Jersey, which has been approved by CMS as an "State Approved Effective Rate Review Program" for QHP certification and rate review, CMS relies on New Jersey approval of the QHP application first, including performing QHP checks for Actuarial Values prior to CMS review and approval. As such, a false or fraudulent misrepresentation to DOBI is also a false or fraudulent misrepresentation to CMS.
- 71. Under the ACA, States will continue to perform their traditional regulatory role for issuers and health plans.

¹⁹ 45 CFR 154.301

VII. THE NEW JERSEY MINIMUM COST SHARING THRESHOLD

- 72. Defendants, as the QHP issuer must be in compliance²⁰ with all State requirements and any provisions imposed by a State in addition to the actuarial value (AV) of the particular plan, meaning that for a standard population, the plan will pay the AV% (70%, 80% or 90%) of their health care expenses, while the enrollees themselves will pay remaining balance (30%, 20%, 10%) through some combination of deductibles, copays, and coinsurance of their health expenses.
- 73. The New Jersey State requirements regarding limits on co-payments that insurers such as AMNJ and AMHMO must also certify compliance with is N.J.A.C. 11:22–5.5 Network Co-payment, which states:
- (a) Network copayments in health benefit plans and stand-alone prescription drug plans may not exceed the following amounts:
 - 1. Preventive services, \$30.00;
 - 2. Primary care provider office visit, \$50.00;
 - 3. Specialist physician office visit, \$75.00;
 - 4. Emergency room visit, \$100.00;
 - 5. Outpatient surgery, \$500.00;
 - 6. Inpatient admission, \$500.00 per day up to a maximum of \$2,500 per admission;
 - 7. Magnetic resonance imaging, computerized axial tomography and positron emission tomography, \$100.00;
 - 8. Generic drug, \$25.00 per 30-day supply;

²⁰ QHP Issuer Minimum Certification Standards set forth in 45 C.F.R. 156.200(b) state that with respect to each of its QHPs on an ongoing basis, the Certification Standards, include inter alia, adherence to the State requirements and any provisions imposed by a State its QHPs. 45 C.F.R. 156.200(d)

- 9. Preferred drug, \$50.00 per 30-day supply;
- 10. Non-preferred drug, \$75.00 per 30-day supply; and
- 11. For any other services and supplies, the copayment is to be determined so that the carrier insures 50 percent or more of the aggregate risk for the service or supply to which the copayment is applied. (This section would be the operative requirement involving the services at issue here, i.e., physical therapy, occupational therapy, speech therapy and chiropractic services.)

VIII. THE DEFENDANTS QUALIFIED HEALTH PLANS IN NEW JERSEY

74. Defendants had individual enrollees in a QHP in New Jersey for which it receives APTC, CSR subsidies and reinsurance as follows:

INDIVIDUAL PLAN	2014 ENROLLEES	2015 ENROLLEES
AMNJ	25,373	13,003
AMHMO	79,447	38,354
TOTAL	104,820	51,357

These plans include:

- 1. 8 QHPs in violation for 2014
- 2. 6 QHPs in violation for 2015.

Each QHP can contain up to 7 variant plans. Variant plans are all identical as far as the benefit structure is concerned, but they differ in order to offer cheaper co-pays, coinsurance, and deductibles to low income members.

75. The Plans²¹ in violation are set forth below:

²¹ The ID number for the Plans set forth below is assigned by CMS and is the identification number for the Plan in the CMS HIOS (Health Insurance Oversight System)

AmeriHealth NJ Plans in Violation of NJ Minimum Standards

2014

Base Plans

<u>Variant Plans</u>

Metal <u>Level</u>	Plan <u>Name</u>	On Exchange	Off Exchange	73% AV	87% AV	94% AV
Bronze	NJ Tier 1 Advantage Bronze EPO	91762NJ 0070004- 01	91762NJ 0070077- 00			
Silver	NJ Premium Silver EPO	91762NJ 0070005- 01	91762NJ 0070063- 00	91762NJ 0070005- 04	91762NJ 0070005- 05	
Silver	NJ Standard Silver EPO	91762NJ 0070006- 01	91762NJ 0070064- 00	91762NJ 0070006- 04	91762NJ 0070006- 05	
Silver	NJ Tier 1 Advantage Silver EPO	91762NJ 0070007- 01	91762NJ 0070065- 00	91762NJ 0070007- 04	91762NJ 0070007- 05	
Silver	NJ Select Silver HMO	77606NJ 0040001- 01	77606NJ 0040051- 00	77606NJ 0040001- 04	77606NJ 0040001- 05	
Gold	NJ Standard Gold EPO	91762NJ 0070010- 01	91762NJ 0070067- 00			

Silver	NJ	91762NJ	91762NJ	91762NJ	91762NJ	91762NJ
	Cooper Advantage EPO	0070008- 01	0070008- 00	0070008- 04	0070008- 05	0070008- 06

Silv	oper 0070009- over emium OS Plus 91762NJ	91762NJ 0070009- 00	91762NJ 0070009- 04	91762NJ 0070009- 05	91762NJ 0070009- 06
------	---	---------------------------	---------------------------	---------------------------	---------------------------

<u>2015</u>

Base Plans

<u>Variant Plans</u>

Metal <u>Level</u>	Plan <u>Name</u>	On Exchange	Off Exchange	73% AV	87% AV	94% AV
Bronze	NJ Tier 1 Advantage Bronze EPO	91762NJ 0070004- 01	91762NJ 0070004- 00			
Bronze	NJ Community Advantage Bronze EPO	91762NJ 0070081- 01	91762NJ 0070081- 00			
Silver	NJ Standard Silver EPO	91762NJ 0070006- 01	91762NJ 0070064- 00	91762NJ 0070006- 04	91762NJ 0070006- 05	
Silver	NJ Tier 1 Advantage Silver EPO	91762NJ 0070007- 01	91762NJ 0070065- 00	91762NJ 0070007- 04		
Silver	NJ Premium Silver POS Plus	91762NJ 0110002- 01	91762NJ 0110002- 00	91762NJ 0110002- 04	91762NJ 0110002- 05	
Silver	NJ Select Silver HMO	77606NJ 0040001- 01	77606NJ 0040051- 00	77606NJ 0040001- 04	77606NJ 0040001- 05	

Silver NJ Community Advantage EPO	91762NJ	91762NJ	91762NJ	91762NJ	91762NJ
	0070008-	0070008-	0070008-	0070008-	0070008-
	01	00	04	05	06

- 76. In order to get certification, all plan variations must be approved before plan can be offered. Including the base plan and each variation in the count, there are 20 plan variations in 2014 and 19 plan variations in 2015.
- 77. According to CMS, total enrollment for all insurers in New Jersey under QHPs, and the percentage who received Cost Sharing Reduction through APTCs for 2014 and 2015 was as follows:

7	Fotal	APTC	% enrollment	CSR %	6 CSR
Year I	<u>Enrollment</u>	Enrollment	With APTC	$\underline{\text{Enrollment}}$	$\underline{\text{Enrollment}}$
2014^{22}	208,467	172,345	82.7%	108,314	52.0%
2015^{23}	249,395	205,242	82.3%	129,277	51.8%

 $^{^{22}} https://www.cms.gov/newsroom/mediareleased at a base/fact-sheets/2015-fact-sheets-items/Table-1-widget.html$

²³https://www.cms.gov/Newsroom/MediaReleaseDatabase/Fact-sheets/2016-Fact-sheets-items/2016-06-30.html

IX. DEFENDANT'S FRAUDULENT COST SHARING VIOLATES NEW JERSEY STANDARDS

A. Defendants Violation of N.J.A.C. 11:22–5.5(a)11 Relating to Physical Therapy, Speech Therapy, Occupational Therapy and Chiropractic Services

- 78. Relator alleges that Defendants knowingly committed fraud by charging co-pay amounts in excess of the statutory maximum (\$50 and above) to its members for chiropractic, physical therapy, occupational therapy, and speech therapy services for certain Qualified Health Plan in contract years 2014 and 2015 that exceeded 50% of its average cost for these services.
- 79. These copay amounts (\$50, \$60 and \$75) are in violation of New Jersey State regulation, entitled Network Copayment, N.J.A.C 11:22-5.5(a)11 for minimum standards, which states that a network copayment shall be set so that the carrier insures 50% or more of the aggregate risk for the service or supply to which the copayment is applied. Specifically, for 2014, the copay amounts of \$50, \$60 and \$75 were in violation. For 2015, the copays of \$60 and \$75 were in violation.
- 80. In 2014, Relator, as part of his assigned duties, calculated the correct average claim cost amount to be ninety three dollars and sixty nine cents (\$93.69) and reported these figures to his superior, Mark Robinson, the director of Actuarial Services. By maintaining co-pays of \$50, \$60 and \$75 dollars in its QHPs, Defendants exceeded the maximum allowable co-payment.

- 81. By violating the New Jersey Network Copayment Minimum Standards for QHPs plans offered under the Affordable Care Act, AMNJ and AMHMO also violated the False Claims Act by procuring contracts to offer these QHPs under false pretenses. Defendants received more than \$133 million in subsidies related to these QHPs that did not meet the minimum standards for state certification and subsequent federal certifications.
- 82. AMNJ and AMHMO knowingly submitted certain health insurance plans (knowing that such plan designs did not meet the minimum requirement) to be approved and accepted as QHPs in order to be eligible for placement on a Federal Facilitated Exchange and receive subsidies from the Federal Government, including payments of premium tax credits, cost-sharing reductions, and reinsurance from CMS. These violations would have prevented their State approvals, and subsequent federal approvals from CMS qualifying and certifying the plans as QHPs.
 - B. Defendants Were Aware of The Violations Since 2011
- 83. In 2011, Defendants received inquiries from New Jersey Department of Banking and Insurance (DOBI) based on a rejection of the filing of certain plans, which raised questions about the amount of the co-pays for rehabilitative and habilitative type services.
- 84. Actuaries at IBC were asked to verify that these therapy services were in compliance with the co-pay limitations set forth in New Jersey's Network Copayment requirements at N.J.A.C. 11:22-5.5(a)11.

- 85. In reviewing the data, IBC actuarial analyst Rebecca Alvarado realized that the Plans in question were not in compliance. Alvarado reported her findings to Beth Forman, Director of Actuarial Services.
- 86. In order to show compliance (or hide the lack of compliance), IBC used averaged cost and claims data from not only physical therapy, speech therapy, occupational therapy and chiro, (the services in question) but included such unrelated services as chemotherapy codes, cardiac rehab codes, pulmonary codes, cognitive therapy codes, respiratory therapy codes, and even procedures related to pulmonary, cardiovascular, chemistry and toxicology.
- 87. The inclusion of these unrelated services was designed to raise the average costs to show compliance. Once they did so, Defendants represented to DOBI that the Plans were in compliance and it was reported to the New Jersey Department of Banking and Insurance (DOBI) that Amerikeatlh's plans were in compliance. [See Exhibit C, email chain from July 2011 between Beth Forman, Director of Actuarial Services and Becky Alvarado, discussing the inclusion of other services designed to raise the average cost.]
- 88. Although it was Defendant's responsibility to ensure compliance for each health plan offered in the State of New Jersey, AMNJ and AMHMO continued to charge \$50, \$60 and \$75 copays despite their average claim costs being as low as \$50 for certain services (e.g. Chiropratic Services).

- 89. Given that their average claim costs were only \$50, Defendants should have not have charged over \$25 copays (50% of the \$50 average claim cost).
 - C. Certifications in QHP Applications by Defendants to CMS Were False
- 90. In 2013, AmeriHealth received both state and federal certifications to offer QHPs both on and off exchange in New Jersey for 2014, which were re-certified for 2015. The plan designs submitted for certification contained copays (\$50, \$60 and \$75) that were in violation of N.J.A.C 11:22-5(a)11. AmeriHealth knew that it's plan designs were not in compliance with N.J.A.C 11:22-5(a)11.
- 91. Notwithstanding that Defendants were aware of its noncompliance since 2011, at the time of application to CMS for QHP approval for the Exchanges and eligibility for APTC and CSR payments, Defendants took no action and falsely certified compliance which CMS relied on and which was intended to deceive CMS.

D. The 2014 Review

92. In June 2014, as described herein, based on a complaint from a provider questioning the \$50 co-pay, the New Jersey DOBI, Consumer Protection Department, requested that Defendants demonstrate that their \$50 co-pays complied with N.J.A.C 11:22-5(a)11 for Chiropractic Services. IBC, as they did in 2011, included inappropriate codes and services in the data to ensure that their "average cost" would be in compliance in relation to the co-pay limits in N.J.A.C 11:22-5(a)11.

- 93. On or about June 19, 2014 Gale Simon the Assistant Commissioner of the Consumer Protection Services at the DOBI contacted Defendants to advise them that they had received a complaint from a chiropractor regarding AmeriHealths imposition of a \$50.00 copay on network chiropractic services. Simon expressed concern that a \$50.00 copay on a network chiropractor service may not be consistent with N.J.A.C. 11:22-5(a)11 which states that a network co-payment shall be set so that the carrier insures 50 percent more of the aggregate risk for the service or supply to which the co-payment is applied. [See email chain attached hereto as Exhibit B].
- 94. On July 3, 2014 Mark Robinson, Director of Actuarial Services for IBC responded to Gale Simon and Vance Neal at the DOBI that AmeriHealth has interpreted the code to require that co-payments applicable to therapeutic manipulations and therapy services average less than 50 percent of the aggregate risk of these services. Robinson indicated that they believed, based on AmeriHealth, calculations that the average cost per visit was \$154.45 thus in compliance with the \$50.00 copay. [See email chain attached hereto as Exhibit B].
- 95. Upon receiving that information Gail Simon from DOBI asked for a list of the CPT service codes that were included in the analysis and to identify the provider types who submitted claims, for example, medical doctors, chiropractors, physical therapists, etc. Robinson responded by email July 16, 2014 advising that the claims were made up of six different service codes being service codes 2034

occupational/speech therapy; 2035 physical therapy; 2037 chiropractic; 3034 occupational/speech therapy; 3035 physical therapy; and 3037 chiropractic. (Collectively the "Rehab Services Codes") This included both participating and nonparticipating providers. [See email chain attached hereto as Exhibit B].

- 96. DOBI advised Robinson that it was inappropriate to include the amounts for out-of-network services as the test is for a "network co-pay" and therefore should only include the allowed amount for network services. Simon from DOBI also instructed Robinson to remove claims with deductibles and coinsurance. Upon receiving this information Robinson recounted the claims data, in this case reporting a claim average of \$147.90 per visit thus being well within the 50 percent threshold with the \$50.00 copay.
- 97. DOBI continued to press Robinson with respect to the calculation and inquired why J codes (used for orally administered medications), S codes (private payer codes), and C codes (temporary 5-digit HCPCS codes assigned to certain new medical devices and supplies eligible for a passthrough payment) were included in the calculation, as well as services rendered by medical doctors and hospitals. See, Simon email of July 23, 2014, at Exhibit B. DOBI requested a conference call to discuss the issue.

After the conference call, Robinson, on behalf of Amerihealth, responded to Ms. Simon on July 25, 2014. [See, Exhibit B.] Ms. Simon had, during the conference call,

permitted Amerihealth to calculate its average costs by combining costs from chiropractic, physical therapy, occupational therapy, and speech therapy.

- 98. Robinson recalculated Amerihealth's average costs, to include only network services of chiropractic care, physical therapy, occupational therapy and speech therapy. For these services, Robinson reported to DOBI that AmeriHealth's fully insured claims averaged \$100.70 per visit. The conclusion of this average was that the \$50.00 co-pay only represented 49.7 % of the aggregate risk of these services. [See Exhibit B].
- 99. Upon learning about this shortly thereafter in August 2014 Relator advised Robinson that his calculations with respect to this claim and the information that he had represented to DOBI was inaccurate and misleading, stating "by excluding claims where both Deductible = 0 and Coinsurance = 0" was essentially counting plans where the members already reached the out of pocket maximum (no member liability claims), that was falsely raising the average AmeriHealth cost.
- 100. Relator recalculated the claim and found that the average cost for 2014 for the Rehab Services Codes was \$93.69 and reported this to Robinson, along with the calculations, a summary of which is set forth below:

MONTH	Number of Claims for Service Codes	Plan Liability	Member Liability	Allowed Cost
2014-01	7,890	68.93	30.92	99.85
2014-02	7,791	63.54	30.53	94.08

2014-03	8,268	59.24	33.10	92.33
2014-04	8,346	57.77	32.94	90.71
2014-05	7,789	58.90	32.79	91.69
2014 to Date	40,084	61.61	32.08	93.69

[See Relators NJ Therapeutic Service Code Analysis forwarded to Mark Robinson on August 5, 2014 along with summary analysis, attached hereto as Exhibit D].

- 101. In order to appear that AmeriHealth was in compliance with N.J.A.C. 22:11-5.5(a)11, Robinson was using claims where member liability equal zero due to the members being in plans which were designed for 100 percent coinsurance or the member reached their out of pocket maximum (OOP max). Robinson did so, knowingly by the clear and plain meaning of the regulation, along with DOBI expressed intentions, that the test only applied to claims where there was a "copayment" from a Plan that was "in network," especially since the title of N.J.A.C. 22:11-5.5(a) is "Network Copayment."
- applied much like the deductible/coinsurance scenarios and should be excluded from the data, resulting in the \$93.69 average cost. In responding to Relator, Robinson acknowledged that it was "intentional" and refused to report the accurate average cost to DOBI. [See email dated August 8, 2014 from Robinson to Relator attached hereto as Exhibit E]

- 103. Defendants also sold plans with \$60 and \$75 copays that were also in violation for Chiropractic Services, Physical Therapy, Occupational Therapy, and The average claim cost was calculated for the Rehab Service Codes all four services combined. While the regulation clearly states that each "service" should be within the co-pay limitation, DOBI allowed Defendants to combine the Rehab Service Codes because they are similar (rehabilitation related) and sometimes can be mis-coded by providers (e.g., a Chiro visit may get coded and a PT visit). However, there was no basis, or agreement to use such unrelated services as chemotherapy, cardiac rehab, pulmonary, cognitive therapy, respiratory therapy, and even procedures related to pulmonary, cardiovascular, chemistry and toxicology in the average cost calculation.
- 104. Ultimately AmeriHealth reported a false average claim cost of \$100.89 to justify the \$50 copay and did not notify DOBI of the \$60 and \$75 copays that clearly violated both the truthful \$94 average claim cost and the false \$100.89 average claim cost amount reported to DOBI.

E. The 2015 Review

- 105. In 2015, AmeriHealth was asked by another Department within DOBI to justify their \$75 copays, and again, AmeriHealth made specific representations that their plans were in compliance and failed to disclose that their \$75 copays (and \$60 copays) did not comply with N.J.A.C 11:22-5(a)11.
- 106. For contract years 2014 and 2015, AmeriHealth falsely obtained certifications for its QHPs and received (based on both express and implied

certifications which were knowingly false) over \$133 million in subsidies including cost share reduction payments, premium subsidy payments (Advanced Premium tax Credits), reinsurance payments, and risk corridor payments. In fact, as far back as the 2011 Inquiry (see ¶ 83-89), and DOBI's rejection of Defendants filing and methodology to show compliance, demonstrates that its false submissions and certifications of its QHP for approval by DOBI in 2014 and 2015 were material and done knowingly.

X. DEFENDANT'S VIOLATION OF THE FALSE CLAIMS ACT

A. The False Claims Act

- 1. The FCA And False Certification
- 107. The FCA is "intended to reach all types of fraud, without qualification, that might result in financial loss to the government." United States V. Neifert-White, 390 U.S. 228, 232 (1968). Relators allege that Defendants violated the FCA by causing the submission of false claims²⁴ all in violation of 31 U.S.C. § 3729(a)(1)(A). This section imposes liability on any person who "Knowingly presents or causes to be

²⁴ The Federal FCA defines a "claim" to include any request or demand, whether under contract or otherwise, for money or property which is made to a contractor, grantee, or other recipient if the United States Government provides any portion of the money or property which is requested or demanded, or if the Government will reimburse such contractor, grantee, or other recipient for any portion of the money or property which is requested.

presented a false or fraudulent claim for payment or approval"; 31 U.S.C. § 3729(a)(1)(A), as amended May 20, 2009.²⁵

- 108. "Knowingly" means the defendant (1) had actual knowledge that the claim is false; or (2) acted with deliberate ignorance of the truth or falsity of the claims; or (3) acted with reckless disregard of the truth or false of the other claim. 31 U.S.C. § 3729(b)(1)(A)(1-3) and Section 2729(b)(1)(B).
- 109. A false certification establishes the "falsity" of a claim under the FCA. This was emphasized by Congress in the 1986 Amendments to the FCA stating "each and every claim submitted under a contract, loan guarantee or other agreement which was originally obtained by means of false statements or other corrupt and fraudulent conduct, or in violation of any statute or appropriate regulation, constitutes a false claim." S.Rep. No. 99-345 at 9 (1986), reprinted in 1986 U.S.C.C.A.M. 5266, 5274.
- 110. The Third Circuit, in Wilkins and Willis ex rel USA v. United Health Group, (June 30, 2011)²⁶, adopted the implied certification theory under the False Claims Act. In addition, the Third Circuit also indicated in Wilkins that no specific claim need be identified at the pleading stage in an action under the FCA to state a cause of action under the implied certification theory. To establish a claim under §

²⁵ The Fraud Enforcement Recovery Act of 2009, Pub.L. No. 111-21, § 4, 123 Stat. 1616 (2009) modified and renumbered the subsections of § 3729(a) ("FERA").

²⁶ See Third Circuit Docket, Case No 10-2747, Document 003110580261 filed 6/30/2011

3729(a)(1)(A) of the FCA, a relator "must prove that '(1) the defendant presented or caused to be presented to an agent of the United States a claim for payment; (2) the claim was false or fraudulent; and (3) the defendant knew the claim was false or fraudulent.' "United States ex rel. Wilkins v. United Health Group, Inc., 659 F.3d 295, 304–05 (3d Cir.2011) (quoting United States ex rel. Schmidt v. Zimmer, Inc. ("Zimmer I"), 386 F.3d 235, 242 (3d Cir.2004)) (referring to previous codification of the statute as § 3729(a)(1)).

- 111. Section 3729(a)(1)(A) requires only that a claimant present a 'false or fraudulent claim for payment or approval' without the additional element of a 'false record or statement.' Id. Thus § 3729(a)(1)(A) allows a relator to bring a claim based on a defendant submitting a claim for government funds without explicitly making a false statement.
- 112. A legally false FCA claim is based on a 'false certification' theory of liability." Id. A claim is legally false when the claimant knowingly falsely certifies that it has complied with a statute or regulation which is material to the government's decision whether to make payment for the goods or services. Within the theory of false certification, there are two further categories: express and implied false certification. A defendant violates the FCA under express false certification when, in conjunction with a request for Federal funds, it certifies that it is in compliance with regulations that are requirements for payment.

- 113. An FCA violation occurs under implied false certification when a Defendant submits a claim for payment that makes specific representations about the goods or services provided, but knowingly fails to disclose the noncompliance with a statutory, regulatory, or a contractual requirement. In these circumstances, liability may attach if the omission renders those representations misleading. This is the substantially same scenario and facts presented in the TAC. United States ex rel. Escobar 579 U.S._, 2016 WL 3317565, slip op., No. 15-7 (June 16, 2016),
- 114. Liability under the FCA occurs under the implied certification for those who submit claims that make fraudulent misrepresentations, which include misleading omissions if they render the representations misleading with respect to the goods or services. Specifically, representations, like the ones present here, that fall within the rule that "half-truths" representations that state the truth only so far as it goes, while omitting critical qualifying information can be actionable.
 - 2. AmeriHealth's Failure to Comply With N.J.A.C.11:22-5.5(a)(11) Was Material to the Government's Payment Decision
- 115. Being a valid QHP was material to the Government payment decision.

 Defendants fraudulently obtained Qualified Health Plan certification from New

 Jersey DOBI. Had the Government payers, HHS and CMS, known this, it would not, and as a matter of law, could not, pay Defendants subsidies or reimbursements for claims submitted by them.
- 116. The Supreme Court, in Escobar reaffirmed that the proper test for determining materiality in FCA cases is whether the conduct at issue has "a natural

tendency to influence, or [is] capable of influencing, the payment or receipt of money or property." 136 S. Ct. at 2002 (citing 31 U.S.C. § 3729(b)(4); Neder v. United States, 527 U.S. 1, 16 (1999); Kungys v. United States, 485 U.S. 759, 770 (1988)).

This approach is consistent with the statutory text of the FCA, which was amended in 2009 to expressly incorporate the "natural tendency" test, thereby rejecting a more onerous "outcome materiality" standard that some courts had adopted. See Pub. L. No. 111-21 at § 4 (2009) (The Fraud Enforcement and Recovery Act of 2009 ("FERA")).

3. Factors to Consider In Natural Tendency Test

- 117. The Supreme Court in Escobar identified a variety of factors bearing on this holistic assessment, including whether:
 - 1. whether the requirement violated is a condition of payment, Id. at 2003;
- 2. whether the requirement violated is significant or "minor or insubstantial," Id.;
- 3. whether the violation goes to the "essence of the bargain," Id. at 2003 n.5 (quoting Junius Const. Co. v. Cohen, 257 N.Y. 393, 400 (1931)); and
- 4. how the Government has treated similar violations when it had "actual knowledge" of them, Id. at 2003-04.
- 118. Importantly, Escobar makes clear that no one factor is dispositive, and a court must evaluate these factors together to determine whether a particular violation is material. Id. at 2001 (citing Matrixx Initiatives, Inc. v. Siracusano, 563

U.S. 27, 39 (2011) (materiality cannot rest on a "single fact or occurrence as always determinative")); accord; United States ex rel. Escobar v. United Health Services, Inc., No. 14-1423, slip op. at 15 (1st Cir. Nov. 22, 2016) (employing Supreme Court's "holistic approach" to materiality analysis).

- condition of payment, the underlying statute and regulations have deemed compliance with the provisions of the ACA a condition of payment. See Section 1313(a)(6) of the Affordable Care Act states provides that "payments made by, through, or in connection with an Exchange are subject to the False Claims Act (31 U.S.C. 3729 et seq.) if those payments include any Federal funds. Compliance with the requirements of the ACA concerning eligibility for a health insurance issuer to participate in the Exchange shall be a material condition of an issuer's entitlement to receive payments, including payments of premium tax credits and cost-sharing reductions, through the Exchange."
- 120. 45 C.F.R. 156.2000(d) makes it clear that issuers must comply with state exchange requirements for certification of QHPs. In addition, ACA section 1313(a)(b) makes it clear that violations with respect to eligibility to participate is material condition for government payments. This factor certainly points to "materiality."
- 121. The second factor, whether the requirement violated is significant or "minor or insubstantial." also points to Defendants violation being material. Being a qualified health plan by the State of New Jersey is not only clearly significant, it is

essential. Had the New Jersey Department of Banking and Insurance (DOBI) known that the Defendants submitted untested and false data in order to "show" compliance it would not have certified or approved Defendants health insurance plans.

First, these regulations, and it's underlying purpose is central to maintaining the integrity of the ACA, the primary purpose of which was to help individuals and small employers purchase affordable health insurance coverage and provide financial assistance to cover some or all cost sharing for essential health benefits. Violations of these cost sharing mandates only acts to unlawfully and unnecessarily increase the cost of these essential health benefits.

Second, these violations impact tens of thousands of individuals in New Jersey. Together, Defendants insured 104,820 individual in 2014 and 51,357 in 2015 in QHPs that allegedly were in compliance with FFE and New Jersey State insurance requirements that impacted hundreds of dollars of actual out of pockets costs for low income individuals and families.

Third, violation of the copayment standard for these Rehab Services can be particularly substantial, especially to low-to moderate income individuals and families because, by there very nature, these services, and the corresponding copays, are repetitive in nature. Typically, when someone needs any these services (Speech, PT, OT or chiro) it involves many visits. Each such visit has a copay. The excessive cost could likely involves hundreds of actual out of pocket costs for enrollees.

This factor demonstrates "materiality."

- 122. The third factor, whether the violation goes to the "essence of the bargain," also points to Defendants violation being material to the extent that the definition of "essence" means "that which is indispensable." The essential "bargain" under the ACA is the Government's agreement to provide financial assistance (Cost Sharing Reductions, APTCs) for individuals to purchase health insurance and share costs. The other side of the "bargain" is that the ACA requires most individuals to have health insurance beginning in 2014. Violations of mandates to limit the "cost sharing" frustrate this bargain.
- 123. The indispensable or essence of the "bargain" requires that Insurers who seek to sell QHPs on the Exchanges to reduce cost-sharing for low-and moderate-income people earning between 100 percent and 250 percent of the federal poverty level. The Defendants actions goes directly to raising the out of pocket expenses incurred for these very individuals and families. Essentially, even though they are receiving from CMS a CSR for these reduced out of pocket costs, Defendants nevertheless also receiving a "hidden" subsidy by overcharging copays to their members.
- 124. These actions work to frustrate the very heart of what the ACA was intended to achieve. As of 2016, as many as 7 million Americans may have plans with these cost-sharing reductions. In the largest markets in the 38 states using the federal website for marketplace enrollment, the cost-sharing reductions substantially

²⁷ See Black's Law Dictionary, West, Revised 4th Edition, page 642

lower projected out-of-pocket costs for people who qualify for them²⁸. According to the Centers for Medicare and Medicaid Services, growth in household out-of-pocket health care spending slowed from 2.1 percent in 2013 to 1.3 percent in 2014.²⁹

125. The Affordable Care Act's cost-sharing reductions are playing a critical role in limiting out-of-pocket cost exposure for low- and moderate-income people enrolled in marketplace plans. Defendants knowingly violation of State mandates, whose sole purpose is to control of limit the out of pocket cost goes to the essence of the bargain. This factor demonstrates "materiality."

similar violations when it had "actual knowledge" of them, points to materiality. When DOBI became aware of the violations of the New Jersey network co-pay regulation N.J.A.C 11:22-5(a), it has instituted enforcement action. See Consent Order dated September 17, 2015 of the New Jersey DOBI Order E15-106³⁰, Fine Freelancers Consumers Operated and Oriented Program of New Jersey, Inc. Freelancers issued plans that had a \$50 and \$75 co-pays for certain services that did not satisfy the 50% test found in N.J.A.C 11:22-5(a) which is at issue here. Freelancers was forced to, and did agree to reprocess claims and pay a fine. This action by DOBI was specifically directed to "the plans and benefits template used on

²⁸ S. R. Collins and D. Blumenthal, "New Federal Survey Shows Gains in Private Health Coverage and Fewer Cost-Related Problems Getting Care," The Commonwealth Fund Blog, Feb. 24, 2016.

²⁹ S. R. Collins and D. Blumenthal, "New U.S. Health Care Spending Estimates Reflect ACA Coverage Expansions and Higher Drug Costs," The Commonwealth Fund Blog, Dec. 4, 2015.

³⁰ See Order attached hereto as Exhibit G, page 4 of 7.

Federal Facilitated Marketplace to describe its change cost sharing." This action, post certification, once they became aware of the fraud, is consistent with the 2011 Inquiry³¹ and DOBI's rejection of Defendants filing, demonstrates how they treated similar false submissions violations. These examples of prior conduct strongly points to materiality.

- 127. Had the United States and the Department of Health and Human Services ("HHS"), and its Centers for Medicare & Medicaid Services ("CMS"), the administrators and the Government payers of the ACA known that the Defendants fraudulently obtained Qualified Health Plan certification from New Jersey Department of Banking and Insurance (DOBI) it would not, and as a matter of law, could not, pay Defendants subsidies or reimbursements for claims submitted by them.
- 128. Even if the Government had actual knowledge (which it did not) and continued to pay claims, such action does not necessarily undermine a materiality finding because there are many good reasons, including important public policy and safety considerations, why the government might continue to pay claims in such circumstances. See U.S. ex rel. Harrison v. Westinghouse Savannah River Co., 352 F.3d 908, 917 (4th Cir. 2003) (the government might have good reason to pay despite the violation because the contract is "advantageous to the government" or too far along to terminate without excessive costs).

 $^{^{31}}$ see ¶ 83-89 herein

- 129. The more essential the continued execution of a contract is to an important government interest, the less the government's continued payment weighs in favor of the government knowledge defense. To find otherwise could lead to perverse outcomes; the more dependent the government became on a fraudulent contractor, the less likely it would be to terminate the contract (and the less likely the contractor would be held liable.") (internal quotations and citations omitted)).
- 130. Indeed, on remand of Escobar from the Supreme Court, the First Circuit rejected the argument that materiality could not be established because Medicaid continued to pay claims after learning of alleged violations. It stated: "[M]ere awareness of allegations concerning noncompliance with regulations is different from knowledge of actual noncompliance." United States ex rel. Escobar v. Universal Health Services, Inc., 842 F.3d 103, 112 (1st Cir. 2016). Escobar makes clear that the relevance of an agency's response depends on whether the agency had "actual knowledge" of fraud, see Escobar, 136 S. Ct. at 2003 (emphasis added); and "mere awareness of allegations . . . is different from knowledge of actual [misconduct]," Escobar, 842 F.3d at 112. Thus, where a defendant is subject to public accusations of fraud but disputes such accusations, it would be premature to impute "actual knowledge" to a contracting agency and to construe the agency's lack of response as definitive proof of the lack of materiality.
- 131. Nothing in Escobar suggests that the government must always initiate proceedings to recoup payments previously made in order to establish that certain types of violations are material to payment. There is no administrative prerequisite

to the bringing of an FCA action. See, e.g., United States ex rel. Aranda v. Community Psychiatric Centers of Okla., Inc., 945 F.Supp.1485, 1489 (W.D. Okla. 1996). This factor demonstrates "materiality."

- overarching framework for assessing materiality: that it "cannot rest on a single fact or occurrence as always determinative." Id. at 2001. Escobar did not sub silentio depart from the statutory and common law definitions of materiality (which support the natural tendency test) and endorse an outcome materiality standard. See also United States ex rel. Winkelman v. CVS Caremark, 2016 WL 3568145, at *8 (1st Cir. June 30, 2016) (noting that Escobar adopted common law understanding of materiality); see Harrison, 352 F.3d at 916-17 (the materiality inquiry focuses on the "potential effect of the false statement when it is made, not on the actual effect of the false statement when it is discovered")³².
- 133. Indeed, if the Supreme Court had intended materiality to turn solely on whether the Government would actually have denied payment had it known of the fraud, it would not have been necessary to identify any other factors relevant to the

In short, the Supreme Court did not purport to impose a heightened test for materiality beyond the "natural tendency" test codified in the False Claims Act and entrenched in the common law, and applied by this Court and others. See United States ex rel. Loughren v. Unum Group, 613 F.3d 300, 307 (1st Cir. 2010) (stating that "a false statement is material if it has a natural tendency to influence, or [is] capable of influencing, the decision of decision making body to which it was addressed"); United States ex rel. Feldman v. Van Gorp., 697 F. 3d 78, 96 (2d Cir. 2012) (test for materiality "does not require evidence that a program officer relied upon the specific falsehoods proven"); United State ex rel. Matheny v. MedcoHealth Solutions, Inc., 671 F.3d 1217, 1228-29 (11th Cir. 2012) (same); United States ex rel. Longhi v. United States, 575 F.3d 458, 469-70 (5th Cir. 2009) (mere potential to influence is sufficient); United States v. Rogan, 517 F.3d 449, 452 (7th Cir. 2008) (rejecting argument that testimony of federal officials that they would not have paid claim was necessary); United States ex rel. Harrison v. Westinghouse Savannah River Co., 352 F.3d 908, 916-17 (4th Cir. 2003).

multi-pronged materiality inquiry. See Escobar, 136 S. Ct. at 2003-04. Rather, Escobar makes clear that the materiality inquiry requires a holistic assessment of the tendency or capacity of the undisclosed violation to affect the Government decision-maker.

- 4. Damages Under the False Claims Act
- 134. The measure of damages the United States is entitled to recover under the FCA is the amount of money the government paid out by reason of the false claims over and above what it would have paid out if the claims had not been false or fraudulent. Marcus, 317 U.S. at 543-545, 63 S.Ct. 379; United States v. Neifert-White, 390 U.S. at 232, 88 S.Ct. 959.
- 135. The government is allowed to recover three times the amount of its damages. 31 U.S.C. § 3729(a). "FCA damages 'typically are liberally calculated to ensure that they afford the government complete indemnity for the injuries done it." United States ex rel. Roby v. Boeing Co., 302 F.3d 637, 646 (6th Cir.2002) (quoting United States ex rel. Compton v. Midwest Specialties, Inc., 142 F.3d 296, 304 (6th Cir.1998)).
- 136. The projected damages for 2014 and 2015, based on the QHPs that were in violation of N.J.A.C. 5.5(a)11 are set forth in detail in Exhibit F. This includes all QHPs offered by Defendants during 2014 and 2015, segregated by the Cost Sharing Reduction subsidy, Reinsurance subsidy and the APTC subsidy.

	Cost Sharing	Reinsurance	Premium	
YEAR	Reduction	Subsidy	Subsidy	TOTAL
	(CSR) Subsidy		(APTC)	
2014	8,298,373	30,344,174	41,125,273	79,767,820
2015	13,048,371	16,289,123	24,504,167	53,841,661
TOTAL	21,346,744	46,633,297	65,692,440	133,609,481

B. Defendant's Implied Certification

137. The Federal FCA, 31 U.S.C. § 3729(a)(1)(A) makes "knowingly" presenting or causing to be presented to the United States any false or fraudulent claim for payment, a violation of federal law for which the United States may recover three times the amount of the damages the government sustains and a civil monetary penalty of between \$10,781 and \$21,563.00 per claim³⁴.

138. An issuer that wishes to offer QHPs through an FFE must meet both applicable State laws and requirements and QHP certification standards. Adherence to the State requirements referenced in 45 C.F.R. 156.200(d)³⁵ and any provisions

[&]quot;Knowingly" means the defendant (1) had actual knowledge that the claim is false; (2) acted with deliberate ignorance of the truth or falsity of the claims; or (3) acted with reckless disregard of the truth or false of the other claim. 31 U.S.C. § 3729(b)(1)(A)(1-3) and Section 2729(b)(1)(B).

Inflation Adjustment Act Improvements Act of 2015 (the 2015 Act), which further amended the Federal Civil Penalties Inflation Adjustment Act of 1990. The 2015 Act updates the process by which federal agencies adjust applicable civil monetary penalties for inflation to retain the deterrent effect of those penalties. The 2015 Act requires that not later than July 1, 2016, and not later than January 15 of every year thereafter, the head of each agency must, by regulation published in the Federal Register, adjust each CMP within its jurisdiction by the inflation adjustment described in the 2015 Act. For violations of the False Claims Act, the interim final rule minimum per-claim CMP's will increase to \$10,781 from \$5,500, and maximum per-claim CMPs will jump to \$21,563 from \$11,000. The increase takes effect August 1, 2015 and applies to violations after November 2, 2015.

^{35 45} C.F.R. 156.200(d) states: . . . (d) State requirements. A QHP issuer certified by an Exchange must adhere to the requirements of this subpart and any provisions imposed by the

imposed by a State's QHPs is impliedly and expressly certified to by the Defendants made implicit representations to CMS in its Applications to CMS for its plans that it sought QHP certification status that its QHP were in compliance with all State requirements. In addition, submitting enrollment numbers for qualified individuals in order to receive APTC and CSR subsidies requiring reaffirmation that its plans were in compliance as certified to in its application.

- C. Defendant's Express Certification
- 139. The Federal FCA, 31 U.S.C. § 3729(a)(1)(B) makes "knowingly" making, using, or causing to be used or made, a false record or statement to get a false or fraudulent claim paid or approved by the Government, a violation of federal law for which the United States may recover three times the amount of the damages the Government sustains and a civil monetary penalty of between \$10,781 and \$21,563.00 per claim.
- 140. Defendants herein made express false certification in it's QHP Applications to CMS for its plans that it sought QHP certification status. In addition, submitting enrollment numbers for qualified individuals in order to receive APTC and CSR subsidies requiring reaffirmation that its plans were in compliance as certified to in its application.

XI. CAUSES OF ACTIONS

A. COUNT ONE - THE FCA: 31 U.S.C. § 3729(a)(1)(A)

Exchange, or a State in connection with its Exchange, that are conditions of participation or certification with respect to each of its QHPs

- 141. All of the allegations set forth herein in paragraphs 1 139 are incorporated herein by reference as if fully set forth at length.
- 142. The Federal FCA, 31 U.S.C. § 3729(a)(1)(A) makes "knowingly³⁶" presenting or causing to be presented to the United States any false or fraudulent claim for payment, a violation of federal law for which the United States may recover three times the amount of the damages the government sustains and a civil monetary penalty of between \$10,781 and \$21,563.00 per claim.
 - B. COUNT TWO THE FCA: 31 U.S.C. § 3729(a)(1)(B)
- 143. All of the allegations set forth herein in paragraphs 1 139 are incorporated herein by reference as if fully set forth at length.
- 144. The Federal FCA, 31 U.S.C. § 3729(a)(1)(B) makes "knowingly" making, using, or causing to be used or made, a false record or statement to get a false or fraudulent claim paid or approved by the Government, a violation of federal law for which the United States may recover three times the amount of the damages the Government sustains and a civil monetary penalty of \$10,781.00 and \$21,563.00.
 - C. COUNT THREE THE FCA: 31 U.S.C. § 3729(a)(1)(C)
- 145. The Federal FCA, 31 U.S.C. sec. 3729(a)(1) (c) makes any person, who conspires to defraud the United States by getting a false or fraudulent claim allowed

[&]quot;Knowingly" means the defendant (1) had actual knowledge that the claim is false; (2) acted with deliberate ignorance of the truth or falsity of the claims; or (3) acted with reckless disregard of the truth or false of the other claim. 31 U.S.C. § 3729(b)(1)(A)(1-3) and Section 2729(b)(1)(B).

or paid, liable for three times the amount of the damages the Government sustains and a civil monetary penalty of between \$10,781.00 and \$21,563.00.

XII. RELIEF REQUESTED

- 146. Relator requests the following relief be imposed against Defendants:
- (a) That the United States be awarded three times the amount of damages which it sustained because of the acts of Defendants pursuant to §3729(a)(1)(A) through (C) of the FCA;
- (b) That Defendants each be held liable for civil penalties of up to \$21,563.00, but not less than \$10,781.00 (as adjusted pursuant to §3729 of the FCA and the Civil Penalties Act), to the U.S. for each and every act in violation of the FCA.
 - (c) That this Court award such interest as is available pursuant to the FCA.
- (d) That in the event the United States intervenes in this action and takes over its prosecution, the Relator be awarded an amount for bringing this action on behalf of the United States of at least 15% but not more than 25% of the proceeds paid to the United States resulting from the trial or settlement of the claim, pursuant to §3730(d)(1) of the FCA;
- (e) That in the event the United States and State Plaintiffs do not intervene in this action, the Relator be awarded an amount for bringing this action for the United States of at least 25% but not more than 30% of the proceeds paid to the United States resulting from the trial or settlement of the claim, pursuant to §3730(d)(2) of the FCA;

- (f) That this Court award reasonable attorneys' fees, costs and expenses to the Relator, which were necessarily incurred in bringing and prosecuting this case, pursuant to §3730(d)(1) or (2) of the FCA; and
- (g) That this Court award such other relief as it deems just, necessary and fair.

Relators requests a trial by jury of all issues so triable.

DATED: August 19, 2019

Respectfully submitted,

Counsel for Plaintiff/Relator

Marc M. Orlow, Esquire

BEGELMAN & ORLOW, P.C.

Marc M. Orlow, Esquire

Ross Begelman, Esquire

Regina D. Poserina, Esquire

411 Route 70 East, Suite 245

Cherry Hill, NJ 08034

Phone: (856) 428-6020

Fax: (856) 428-5485

<u>marc.orlow@begelmanorlow.com</u> <u>regina.poserina@begelmanorlow.com</u>

Exhibit A

NEW JERSEY EHB BENCHMARK PLAN

SUMMARY INFORMATION

Plan Type	Plan from largest small group product, Health Maintenance Organization
Issuer Name	Horizon HMO
Product Name	НМО
Plan Name	Horizon HMO Access HSA Compatible
Supplemented Categories (Supplementary Plan Type)	Pediatric Oral (State CHIP) Pediatric Vision (FEDVIP)
Habilitative Services Included Benchmark (Yes/No)	Yes

BENEFITS AND LIMITS

Constitution Cons				C Benefit Description	D Quantitative	E E	F Limit Units	G Other Limit	H	Fydudone (Ontonelle		*
was selected in Limit Units, aentera description Care and/or treatment by a practitioner must be licrosed and Christian Science a care by a bractitioner or care by a practitioner or care by a practitioner or care by a practitioners. Local aneschesia billed a provent services of BCBA practitioners. Local aneschesia billed a prepared by the care by a provent required. Pre-approval requi	Required if benefit is Limit on Select vered Select vered	(Required if benefit is Covered): Enter a Description, it may be the same as the Benefit name	(Required if benefit is Covered): Enter a Description, it may be the same as the Benefit name	Limit on Service? (Required if benefit is Covered): deet "Yes" if Quantitative		Quantity (Required if Quantitative Limit is "Yes"); Enter Limit	(Required if Quantitative Limit is "Yes"): Select the correct limit units	Units Units Description (Required if "Other" Limit Unit): If a Limit Unit of "Other"	Stay (Optional): Enter the Minimum Stay (in hours) as a	Extensions (upnonau): Enter any Exclusions for this benefit	Enter an Explanation; (Optional) Enter an Explanation for anything not listed	Does this benefit have additional limitations or restrictions? (Required if benefit is
The by a Practitioner must be litensed and acting within the scope of the license, but also cover services of BCBA and BCBA practitioners. No charges Pre-approval required. Additions, Inpatient hospice covered at the private room & board rate, Pre-approval required, Except as the private room & board rate, Pre-approval required, except as No Heat services. See "Other" for covered demtal-related services, find of services, as to Pre-approval required, Except as No Heat specifically excluded, only artificial services, find of engths of treatment and cycles of netuding therapy of Prescription Drugs are membry of membry of membry of prescription brugs are embryon intra-figure.	Limit applies	Limit applies	Limit applies	Linit applies				was selected in Limit Units, enter a description	number			Covered): Select "yes" if there are additional limitations or estrictions that
ment by a Practitioner must be litensed and acting within the scope of the license, acting within the special required. Pre-approval required, becent as the approval required, except as services, act of private room & board rate, pre-approval required, except as liver approval required, except as that, acting the schildred, only artificial services, and the schildred, only artificial for the approval of treatment and cycles of reluding the approval frescription Drugs are necessary of prescription Drugs are necessary. I won or more.	Primary Care Visit to Covered Primary care visit to treat an INA	Covered Primary care visit to froat an	Primary care visit to froat an No.			****						need to be
ment by a Practitioner must be licensed and acting within the scope of the license, but also cover services of BCBA and BCBA practitioners. BCBA practitioners. BCBA practitioners. BCBA practitioners. See "Dther" for covered at the approval required. See "Dther" for covered at the approval required. See "Dther" for covered dental-related services. Fre-approval required, Except as services. See "Dther" for covered dental-related services. See "Dther" for covered dental-related services. See "Dther" for covered at the approval required. Except as services. See "Dther" for covered at the approval required. Except as services. See "Dther" for covered at the approval required. Except as services. See "Dther" for covered at the approval required. Except as services. See "Dther" for covered at the approval required. Except as services. See "Dther" for covered at the approval required. Except as services. See "Dther" for covered at the approval required.	or Illness injury or Illness	injury or illness	injury or liness	á.								ON.
ment by a Practitionier must be licensed and acting within the scope of the license, but also cover services of BCBA and BCBA practitioners. BCBBA practitioners. BCBBA practitioners. Granges Grange	Covered Specialist visit	Covered Specialist visit		0	1							
re by a decling within the scope of the license, re by a a acting within the scope of the license, but also cover services of BCBA and BCBA practitioners. BCBBA practitioners. Grant BCBA practitioners. Grant	ce Cavered	Covered Other practitioner office		o	1					ate and for treatment to		VO.
BCaBA practitioners. billed Pre-approval required. charges draftons, inpatient hospice covered at the private room & board rate, Pre-approval required. See "Other" for covered dental-related set to Pre-approval required, Except as services, set to Pre-approval required, Except as services, find a specifically excluded, only artificial in specifically excluded, only artificial in specifically excluded, only artificial in the specifically excluded, only artificial in the specifically excluded, only artificial in the specifically excluded in services. Including therapy of Prescription Drugs are embryon intra- figirn, fan more.	Assistant) Assistant)		Visits (nurse, physician essistant)						<u>, , , , , , , , , , , , , , , , , , , </u>	rebya	JS 6.	o.
billed Pre-approval required. charges. dations, Inpatient hospice covered at the private room & board rate, Pre-approval required. See "Dther" for covered dental-related set to Pre-approval required. Except as services, as to Pre-approval required. Except as that specifically excluded, only artificial insemination and standard docages, fon of including therapy of Prescription Drugs are intra-grant. sal. sal.	Outpatient Facility Fee Covered Outpatient facility fee No (e.g., Ambulatory Surgery	Covered Outpatient facility fee		0								O.
olilled Pre-approval required. charges dations, inpatient hospice covered at the private room & board rate, Pre-approval required, Except as a services. See "Dther" for covered dental-related services. See "Dther" for covered dental-related services. In Pre-approval required, Except as that specifically excluded, only artificial insemination and standard dosages, fon of lengths of treatment and cycles of relating therapy of Prescription Drugs are milenya covered. Seal. Seal.	7. 1.	7. 1.										ļ
defions, inpatient hospice covered at the private room & board rate, Preprival required, Except as services, set to Pre-approval required, Except as services, find that specifically excluded, only artificial insemination and standard dosages, find of lengths of treatment and cycles of neluding therapy of Prescription Drugs are mingration. Sea. Sea. "Dther" for covered dental-related services in services and standard dosages, find of the process of insemination and standard dosages, find of the process. Sea. Sea. Sea. "Dther" for covered at the process of services of insemination and standard dosages, find of the process of insemination and standard dosages. Sea. Sea. "Dther" for covered at the process of sea. Sea. Sea. "Dther" for covered at the process of sea. Sea. "Definition of the process of	Physician/Surgical Covered Outpatient surgery; No Services Services	Outpatient surgery, physician/surgical services		o.								10
private room & board rate, Pre- approval required. See "Other" for covered dental-related sex to Pre-approval required. Except as that specifically excluded, only artificial 5. storage inserpination and standard dosages, fron of lengths of treatment and cycles of richuling therapy of Prescription Drugs are ring. covered. sea. sea.	Hospice Services Covered Hospice services No	Hospice services		0								oļ
See "Dther" for covered dental-related services. es to Pre-approval required, Except as that specifically excluded, only artificial is storination and standard dosages, fon of lengths of treatment and cycles of richuling thierapy of Prescription Drugs are embryo covered. embryo more	Non-Ernergency Care Not Covered Travel outside U.S.		Travel outside U.S.							10	invate room & board rate, Pre-	
See "Other" for covered dental-related services, service		1		:			***************************************					
services. es to Pre-approval required. Except as that specifically excluded, only artificial storage insemination and standard dosages, nicholog lengths of treatment and cycles of mixeding therapy of Prescription Drugs are embryo covered. sel. sal.	Routine Dental Services Not Covered Routine dental-adult (see		Routine dental-adult (see								Oct With board do a second of the second	
es to Pre-approval required. Except as that specifically excluded, only artificial 5. storage insemination and standard dosages, not of lengths of treatment and cycles of richding therapy of Prescription Drugs are only covered. sal. sal.	Infertility Treatment Covered Impredinfertility freetment No.	Limited infertifity treatment		i		:					ervices.	
embryo transfer, embryo freezhig, gamete intra- fallopian transfer (GiFT), zygote intrafallopian transfer (ZiFT), donor sperm, surrogate motherficiad, or sterifization reversal,				3.			· Auronavidia a La		vi vi as ne ne a	DÚ tra	<i>S</i> ²	Q
transfer (dr. l., tonor sperm, surrogate motherhold, or sterilization reversal.								***************************************	o er er si	nbryo transfer, embryo eezing, gamete intra- liopian transfer (GIFT), gote intrafallopian		
Custodial and domiciliary						70.			<i>3 № °</i> E: L	ansier (21-1), donor perm, surrogate Otherhood, or		<u> </u>
	Long lettiny Lustodial Not Covered LTC/Custodial	Not Covered LTC/Custodial	LTC/Custodial	-						ustodial and domiciliary		-

New Jersey-

N Does this benefit have additional limitations or restrictions? (Required if benefit is Covered): Select "Yea" If there are additional limitations or restrictions that here the described described	No	o o o	No	S.O.O.
Lyplanation; (Optional) Enter an Explanation for anything not listed	Only covered under Home Health Care No Services (see Home Health Care for other Ilmits/conditions).	Eye screenings provided as part of a routine physical exam are covered.		Services furnished to family Pre-approval required. Covers members, other than the medically necessary and appropriate patient. Services and services in a written home health plan supplies not included in the when certified as needed to avoid confinuing hospitalization or confinuing hospitalization or confinuing hospitalization or confinement in a SMF. Services and supplies must be included in the written plan and furnished by a home health agency through recognized health agency through recognized health agency through recognized health agency through recognized health care professionals. The covered person's practitioner must establish the written plan within 14 days after frome health care starts and review it at least once every 60 days.
Exclusions (Optional); Enter any Exclusions for this benefit		Exams to determine the meet for or changes of eyeglasses or lenses of any eyeglasses or lenses of any type (other than initial replacements of the natural lens); eye surgery primarily intended to correct myopia, hyperopia	The state of the s	Services furnished to family members, other than the patient, Services and supplies not included in the tome health care plan.
H Stay Stay (Optional): Enter the Minimum Stay (in hours) as a whole number				
Other Limit Mininum Stay Units Stay Description (Optional): (Required if Enter the 'Other' Limit Mininum Unith: Stay (in li a Limit Unit hours) as a of "Other" was selected number a enter a description				Visit limit is per calendar year
F. Limit Units. (Required if Quantificative Limit is "Yes"); Select tithe correct finit units	Visits per year			Visits per year Visit limit is per calenda year
E Umit Quantity (Required if Quantitative Limit is "yes"): Enter Limit Quantity	09			09
Dutitative Limik on Service? Required if Benefit is Coverad): lect "yes" if uantitative		V	Να	\$0 }
and the		tion).		Home health care services
Covered (Required): (Required): Covered or Not Covered				Coverred
Benefit Physical Drivens			's or	Forvices
Number				

Does this benefit have additional limitations or restrictions? (Required if benefit is Covered); Select "Yes" if there are additional dimitations or restrictions that have a discretive to be described.	ON	No
Explanation: (Optional) Enter an Explanation for anything not listed	No referral or notice required prior, but coverage is provided only if written proof of the cocurrence, nature and extent of the emergency service is submitted writin 30 days. Coverage for emergency services includes only treatment needed to treat the emergency, pre-approval is required for coverage of elective procedures performed after admission as a result of an emergency. Emergency services of non-network providers covered person's symptoms were severe and delay of treatment would have been detrimental to health, the symptoms occurred suddenly and the covered person sought immediate attention, and the service or supply is not normally provided on a non-emergency basis. Includes emergency coom treatment at Level 1 and Level 2. Trauma centers (as required by NJAC.	Covers medically hecessary and Covers medically hecessary and member to a local hospital or to the nearest hospital where needed care can be given, if a local hospital cannot provide such care (but see exclusion).
Exclusions (Optional); Enter any Exclusions for this benefit		Chartered flights, Travel or communication expenses of patients, health care providers or family members. Services for ambulance transport from a hospital to another facility except when a member is transferred to another inpatient health care facility.
H Stay Stay (Optional): Enter the Minimum Stay (in Stay (in hours) as a whole number		
G H Other Limit Minimum Units Stay Description (Optional): (Required if Enter the "Other" Limit Unit hours) as a of "Other" whole was selected number in Limit Units, enter a description		
F Limit Units (Required if Quantitative Limit is "Yes"); Select the correct limit units		
E Limit Quantity (Required if Quantitative Limit is "Yes"); Enter Limit Quantity		
Quantitative Limit on Service? Required if benefit is Covered): Select "Yes" if Quantitative Limit applies	<u>9</u>	No.
≥ #	curel Bency room sayvices:	Fransportation/ambulance
to to the second		Covered
Benefit Covered Require Covered Not Covere		Emergency Transportation/ Ambulance
Number		q

k Does this benefit have additional limitations or restrictions? (Required if benefit is Covered); Select "ves" if there are additional limitations or estrictions that	Nd	No		o Z	No	Q	No	No	No
Finter an Explanation: (Optional) Inted Ilsted	required. Covered at room and board rate. ing. Intensive and special finaging and laboratory as and biologicals, presentive care, anesthesia, if medical and obstetrical air medical and obstetrical and obstetrical	services, etc. Pre-approval required for surgery.	Pre-annious required	Defined as any surgery or procedure that involves physical appearance that does not correct or materially improve a physical function and is not medically necessary.	Pre-approval required. Coverage of network SNF services and supplies only for those constituting skilled nursing	See "Delivery and All inpatient Services Mo for Maternity Care," Mother may elect a home care program in lieu of the post-delivery hospital stay.	I newborn may be covered blours inpatient in a spital affer a sarian delivery if the hysician determines it is ecessary or the mother.	and	Developmental Disabilities. Pre-approval required.
Exclusions (Optional): Enter any Exclusions for this benefit	Private accommodations	arges If nen d in the	er ick use surgery.	Cosmetic surgery, treatment for complications of cosmetic surgery, related services or supplies and drugs provided for cosmetic numbers.	commodations.		Private accommodations:	e, education	Private accommodations, custodial care, education and training.
H Minimum Stay Coptkonal): Enter the Minimum Stay in man Mumber number							48		
Other Limit Minimum Units Stay Description (Optional): (Required if Enter the Other Limit Minimum Unit): If a Limit Unit Mours) as a of "Other" whole whole was selected number after a description				And the same and the same					
F. Limit Units (Required if Quantitative Limit is "Yes"): Select the correct limit units									
E Limit Quantity (Required if Quantitative Limit is "Yes"); Enter Limit Quantity							;		,
D Quantitative Limit on Service? [Required if benefit is Covered]: Select "yes" if Quantitative Limit applies	Ç.	No.	No		ON	NO.	9	Na	No
Benefit Description (Required if benefit is Covered): Enter a Description, it may be the same as the Benefit hame		an and		rut, covered See excussion and Explanation				Wental/behavioral health N	
Covered (Required): Is benefit Covered or Not Covered			Covered Not Covered	e D					
Benefit	pital	pue ue				Care. Care. California and All Inpatient Invaries	Services for Maternity Care	Mental/Behavioral Health Covered Outpatient Services	Mental/Behavioral Health Covered Inpatient Services
Number 17			20 12		7 2				255

is and a second an	72				
M. Does this benefit have additional limitations or restrictions? (Required if benefit is Covered); Select "yes," if thore are additional limitations or restrictions that need to be	described No	No	No	Ċ	N.
J Enter an Explanation: {Optional} Enter an Explanation for anything not listed		Pre-approval required.	ription/refill for up or 100 unit doses, italy prescribed by italy prescribed by ased on FDA labeling, See	Jones Mormation. Covered per prescription/feffil for up 16 or 30-day supply or 100 unit doses, or the amount usually prescribed by the Network practitioner. Additional limits may apply based on FDA approved product labeling. Preapproved required for certain prescription drugs. See "Other" for additional prescription Drug medicional prescription Drug information.	prescription/refill for up upply or 100 unit closes, it usually prescribed by practitioner. Additional ply based on FDA duct labeling. Pre- lifed for certain. frugs. See "Other" for escription brug
Exclusions (Optional); Enter any Exclusions for this benefit	Custodial care, education	Private accommodations, custodial care, education	Orugs prescribed for Orugs prescribed for cosmetic purposes; nonprescription drugs.	Drugs prescribed for cosmette purposes; nonprescription drugs.	Drugs prescribed for cosmette purposes; nonprescription drugs.
H Minimum Stay (Optional): Enter the Minimum Stay (in hours) as a Whole mumber					
G Other Limit Units Description (Required ff "Other" Limit ff a Limit Unit): ff a Limit Unit was selected in Limit Units, enter a description					
F. Limit Units (Required if Quantitative Limit is "Yes"); Select the correct limits units					
E Limit Quantity (Required if Quantitative Limit is "Yes"]; Enter Limit Quantity			:		
Quantitative Limit on Service? Service? Required if benefit is Coverefit is Coveriff is Quantitative if Quantitative if Limit applies	No	C.	No.	NO.	O _N
C Benefit Description (Required if benefit is Covered): Enter a Description, it may be the same as the Benefit name		Sübstance abuse disorder Inpatient services			Non-preferred brand drugs
B Covered (Required); Is benefit Covered or Not Covered		Covered			Covered
Benefit	Substance Abuse Disorder Covered Outpatient Services	Substance Abuse Disorder Covered Inpotient Services	Generic Drugs	rreverred fitand Drugs	Drigs
Number					

Does this benefit have additional limitations or restrictions? (Required if benefit is Covered); Select "Yes" if there are additional limitations or restrictions that	No .	Na	No.	NG	Na	<u>o</u>	No
I Enter an Explanation for anything not listed	pre- that have stration or and require on prior to sistance sist be y See "Other" well as Anti-		nearth care benefits, Habilitations as provided through I refabilitation services are covered. See also, Hearing Aids, "Other" for Autism and Developmental Disabilities benefits, ST, PT/OT and ABA benefits; "Other" for Diabetes services.	twork	Pre-approval required, must be ordered by a network practitioner land arranged through the carrier.	Covered for members, 15 years old and No younger. The hearing aid must be recommended on prescribed by a ficensed physician or auditologist.	
Exclusions (Optional): Enter any Exclusions for this benefit	Drugs prescribed for cosmetic purposes; nonprescription drugs.						
H Minimum Stay (Optional): Enter the Minimum Stay (in hours) as a whole number						:	
G H Other Limit Minimum Units Stay Description (Optional): (Required if Enter the "Other" limit Minimum Unity: If a Limit Unit Unit wholer in Limit Units, enter a description			Habilitation services are subject to the limits applicable to rehabilitation services, other therapies, services and supplies. See Explanation.		One/hearing-	impaired ear every 24- months	
Limit Units (Required if Quantitative Limit is "Yes"): Select the correct limits units		Visits per year	The state of the s	Visits per year	Other		
E Limit Quantity (Required if Quantitative Limit is "yese"); Eriter Limit Quantity		30.	- F				
D Quantitative Limit on Service? (Required if benefit is Covered): Select "Yes" if Quantitative Limit applies	ŠÓ.	Yes	Yes		Yes		0
Benefit Description (Required if benefit is, Covered): Enter a Description, it may be the same as the Benefit name	N Signative division of the signature of	ation	Rebilitation services Y	***		Bannotic teet (X. ver. sind fal. III	Work)
Covered (Required): (Required): (Subserved): Not Covered Not Covered C			Covered		Cavered	Covered	
Benefit Secially Drurs		Outpatient Rehabilitation Covered Services	Habultation Services. Chiropractic Care	Durable Medical	Equipment Hearing Aids)jagnostic Test	(X-Ray and Lab Work)
Kow Number			r U	2 O	д <u>ж</u>	34	

Does this benefit have additional imitations or restrictions? (Required if benefit is Covered); Select "Yes," if there are additional additional imitations or restrictions that need to be	described		344			
	S C C C	S S			Na Na	N
f Enter an Explanation: (Optional) Fisted Iisted	Pre-approval required, including for CT, PET, MRI, Computed Tomography Adigiography (CTA), Magnetic Resonance Angiogram (MRA), Nuclear Medicine (Including Nuclear	Cardiology). Includes USPSTF recommendations, but see "Other" for additional screening benefits.	Routine foot care is excluded, except for the following: open cutting operations to treat weak, strained, flat, unstable or unbalanced feet, metatistalgia or bunions; removal of nail rooks; treatment of corns, calluses or toenails in conjunction with the treatment of metabolic or peripheral vascular disease. Also, see "Other" for	Orthotics and Prosthetics benefits, Covered when used as a substitute for other forms of anesthesia		Does not provide includes coverage for exams by allowance for both glasses optometrist or ophthmalogist, and contacts in a single including dilation, includes allowances year. No vision therapy, no for lenses, frames, contacts, and discounts for laser surgery when using except as described (see a contracted provider.
Exclusions (Optional): Enter any Exclusions for this benefit		Routine immunizations for the sole purpose of travel or as a requirement for a member's employment				Does not provide allowance for both glasses and contacts in a single year. No vision therapy, no public corrective freatments or flevises, except as described (see "Explanation").
H Minimum Stay (Optional): Enter the Minimum Stay (in hours) as a whole number						
G H Other Limit Minimum Units Stay Description (Optional): (Required if Enter the "Other" Limit Minimum Unit): If a Limit Linit hours) as a of "Other" was selected number in Limit Onits, enter a description						Allowance for eyeglasses (lenses and frames) or contact lenses annually,
F Limit Units (Required If Quantitative Limit is "Yes"): Select the correct limits units					Visits per year	Other
E Umit Quantity (Required if Quantitative Limit is "Yes"); Enter Umit			:			
D Quantitative Limit on Sarvice? (Required if benefit is Covered! Select "Yes," if Quantitative Limit applies	No	ψ			Yes	Yes
Benefit Description (Required if benefit is Covared): Enter a Description, it may be the same as the Benefit name	imaiging (CT/PET scans, MRIs)	Immunîzatio	Not Lovered See Explanation	Not Covered See Explanation Not Covered		ty's glasses for children
Covered (Required): Is benefit. Covered or Not Covered	Covered	Covered	VOI LOVERED	Not Covered		COVERED
	क्षाङ्	Preventive Care/ Screening/Immunization		Acupuncture Weight Loss Programs		
kow Number	33- 33 (n c		42	43	

K Does this benefit have additional funitations or restrictions? (Required if benefit is Covered): Select "Yes" if there are additional limitations or restrictions that restrictions that	described
J Enter an Explanation; (Optional) Iisted	Treatment for TMU; imited Coverage includes screenings and other preventive Services, diagnostic services, and minor restorative Services, major and minor restorative Services, endodontic, surgical and adjunctive services, periodontic and prosthedontic services, as medically necessary. Begins at age 1 year. Dental services also include orthodontia—see
Exclusions (optional); Enter any Exclusions for this benefit	Treatment for TMJ, limited to members age 19 and younger:
H Minimum Stay (Optional); Enter ring Minimum Stay (in hours) as a whole number	
G H Other Limit Minimum Units Stay Description (Optional): (Required if Enter the "Other" Limit Minimum Unit): Stay (in If a Limit Unit hours) as a of "Other" was selected In Limit Units, enter a description	
Imit Units Other Limit Minimum (Required if Units State Limit Is Limit Is "Other Limit Minimum Yes"): "Other" Limit Minimum Select the Unit); Stay (in correct limit of "Other" whole was selected number in Unit Units, enter a description	
E Limit Quantity (Required if Quantitative Limit is "Yes"); Enter Limit Quantity	
D Quantitative Limit on Service? (Required if benefit is Covered); Select "yes" if Quantitative Limit applies	No.:
Benefit Description (Required): (Required if benefit is Senefit Covered or Enter a Description, it may vot Covered be the same as the Benefit name.	Dental Services (per CHIP) N
B Covered (Required): Is benefit Covered or Not Covered	Covered
A Benefit	Dental Check-Up for Children
Row Number	45

New Jersey-10

	-	-	
Ĺ		_	
ζ			

Does this benefit have additional limitations or restrictions? (Required if benefit is Covered): Select 'Yes," if there are additional limitations or restrictions that restrictions that	described Yes	o			0.
Explanation; (Optional) Enter an Explanation for anything not listed	repplies when provided in a network let's office—services provided under alth Care or to treat Autism or nental Disabilities do not apply towards Also note: the benefit limit for the small group plans is combined for de ognitive therapy for a rotal of 30 of the standard Individual plan market, 5 30 visits each for speech and cognitive	Therapy. Limit only applies when provided in a network No practitioner's office—services provided under home Health Care or to treat Autism or Developmental Disabilities do not apply towards this limit. Also notes the benefit limit for the standard small group plans is a combined 30 visit limit for PT and OT, but for the standard individual market, the benefit limit is 30 visits each for PT.	and U1. Limit does not apply against other ST benefits No under the policy. Only available for treatment of diagnosis of autism or developmental disability. Therapy need not be restorative. Therapy received through Early intervention Sarvices does	Limit does not apply against other PT/OT benefits. No under the policy, Only available for treatment of diagnosis of autism or developmental disability. Therapy need not be restotative. Therapy received through Early Intervention Services does received through Early Intervention Services does	Torn members 21 Very annual penditis. For members 21 Very annual very Available to treat. No primary diagnosis of autism. Therapy need not be restorative. Therapy received through Early intervention Services does not reduce any benefit. Thestwent plan by physician required, reviewed services any sermi-annually.
Exclusions (Optional): Enter any Exclusions for this benefit					
H Mihimum Stay (Optional); Enter the Minimum Stay (In Hours) as a whole number					
G Other Limit Units Description (Required If "Other" Limit Unit): If a Limit Unit of "Other" was selected in Limit Units, enter a description	Visits per year year	Visits per year Combined=30/calendar	Visits per year wishs per ralendar year	Visits per year Combined-30/calendar- year	
F Limit Units (Required if Quantitative Limit is "Yes"); Select the " correct limit units	isits per year (Islts per year C	isits per year w	sits per year O	
E Limit Quantity Quantity (Required if Quantitative Limit is "Yes"); Enter Unit Quantity	Ω	0	0	Ö	
Quantitative Limit on Service? (Required if benefit is Covered): Select "Yes" if Quantitative Limit applies	Yes			, 3 7 €5.	&
Benefit Description (Required if benefit is Covered): Enter a Description, it may be the same as the Benefit name		Physical and Occupational therapy y	Autism/Developmental Disabilities - Yes Speech therapy (Habilitative/rehabilitative)	Autism./Developmental Disabilities - Y Physical and Occupational therapy (Habilitative/frehabilitative)	Autism/ Developmental Disabilities - In Applied Behavlor Analysis or Related Structured Behavior Services (Habilitative/rehabilitative)
Covered (Required): Is benefit Covered or Not Covered					Covered
Benefit					3 1 1 1 1 1
Number Benefit	<u> </u>	N e	á		ri .

R Does this benefit have additional limitations or restrictions? (Required if benefit is Covered); Select "Yes" if there are additional limitations or restrictions, they head to be benefit to be additional limitations or restrictions, that head to be additional limitations or restrictions, they head to be a selective to be additional benefit to be a selective to be a selective to be a selective and the selection to be a selective and the selection to be a selection to be a selection to be a selection to a selection to be a selec	described	Να	No	No	NG	No
J Explanation; (Optional) Enter an Explanation for anything not listed	Coverage for charges incurred for medical foods (enteral formulas) and low protein medified food products as determined medically necessary by the member's practitioner for the tharapeutic	Ceatment of inherited metabolic diseases, For infants and toddlers, Covered as If a prescription drug for children diagnosed with multiple food protein intolerance for whom the formula is medically necessary and for whom trials of other non-cow milk-based formulas have	not been successful. Includes the cost of testing and processing of blood. See also "Hemophilia Services."	treatment of oral tumors oval or bony impacted injury to natural teeth or toking natural teeth, if the directly or indirectly, is complete teethory, methodes to of indirectly or indire	related dental ex-rays. Covered: When a member is severely disabled or a No child under age six, general anesthesia and hospitalization for dental services, and dental services and dental services rendered by a dentist regardless of where provided when for a medical condition requiring	nospitalization or general arresthesia. Sugical and nonsurgical treatment of TMJ is covered when medically necessary and appropriate.
Exclusions (Optional): Enter any Exclusions for this benefit			Blood donated or replaced on behalf of a	neriluer. General dental Services, both prophylactic and corrective.	Anesthesia for dental services other than an described under	Expensation Services or supplies for orthodontia, crowns or bridgework,
H Minimum Stay (Optional): Enter the Minimum Stay (in hours) as a whole number	The state of the s					
G Other Linit Units Description. (Required if "Other" Limit Unit; if a Limit Unit of "Other" was selected in Limit Units, enter a description						
E Unit Units (Required if Quantitative Ilmit is "Yes"); "Yes"); Select the correct limit units						
E Limit Quantity (Required if Quantitative Limit is "Yes"): Enter Limit Quantity						
Ouanthative Limit on Service? Required if benefit is Covered; Select "Yes," if Quantitative Limit applies	NO.	NG	Ma	o o	N O	No
C. Benefit Description. (Required if benefit is Covered): Enter a Description, it may be the same as the Benefit name.	70		Blood, blood products and blood. In	- Illnass		Temporomandlaular Joint Disorder N
B Covered (Required): Is bequired): Covered or Not Covered					Covered	Covered
**	1					Other
Number	ا م		∞oz			

K Does this benefit have additional limitations or restrictions? (Required if benefit is Covered); Select "yes" if there are additional limitations or restrictions that need to be	No No		No No	No	No	ON.	NA.	No	No
Explanation: (Optional) Enter an Explanation for anything not listed	fees and expenses are covered for treatment of a No condition associated with a complication of the underlying disease (cancer) through an Approved Cancer Clinical Trial if such fees and expenses would be covered for care and treatment in a situation other than an Approved Cancer Clinical Trial.	Pre-antitracel recording	by an appropriately licensed	by an appropriately licensed	Network provider. Includes both hemodialysis and peritoneal dialysis No and treatment in a dialysis center by an	appropriately itensed network provider. Treatment of disease, diagnostic service requiring tee of radioactive materials is not considered radiation therapy, includes eemal or cost of	in the second	i	
Exclusions (Optional): Enter any Exclusions for this benefit.	Costs of investigational drugs or devices, costs of non-health services, costs trated to managing the research, any costs that would not be covered for treatments that are not Experimental or	Investigational.							
H Minimum Stay (Optional): Enter the Minimum Stay (in hours) as a whole mumber									
G Other Limit Units Description (Required if "Other" Limit Unit): If a Limit Unit of "Other" was selected in Limit Units, enter a description									
F Limit Units (Required if Quantifative Limit is "Yes"): Select the correct limits units									
E Limit Quantity (Reguired if Quantitative Limit is "Yes"); Enter Limit Quantity	Z.								
D Quantitative Unit on Service? {Required if benefit is Covered): Select "Yes" if Quantitative Umit applies	Š	No	oz.	No.	Ö	o Z	No	No	No.
	Cancer Cinical Trials	Pain Management Services (Chalation thornas)				Kadiation therapy	Respiration therapy	Infusion therapy	Farsplants: cornea, kidney, lung, liver, heart, panciess, intestine, allogenic bone marrow
Covered (Required): Is benefit Covered or Not Covered	TOVER BE	Covered				Data da	Covered	Covered	Covered
r Benefit		Other					Other) and the second	Other
Numbe	4.	E 2	£.	3	3.		60	es _k	92

R. Does this benefit have additional limitations or restrictions? (Required it benefit is Covered): Select "yes." If there are additional limitations or restrictions that need to be head to be	described	No	Na	No	No	Na	No	N CA
J Enter an Explanation for anything not listed	er sive uant to	clety of Chincal Oncologists. spital and practitioner services, but med by institutions approved by the ant to protocols consistent with the the American Society of Clinical	Oncologists. Inpatient hospital costs of donors associated with harmsplants if the donor does not have bealth coverage that would cover the medical costs associated with his or her role as a donor	odes cts ated ated rrtain s in-			ogram from ages 35- rams from age 40 on, ien is at risk.	Nequired during childhood,
Exclusions (Optional): Enter any Exclusions for this benefit			Travel, accommodatio ns, or comfort llems.					
H Stay (Optional): Enter the Minimum Stay (in hours) as a whole number								48
GOther Limit Units Description (Required if "Other" Limit Unit): If a Limit Unit; If a Limit units, If a Limit Units, other" was selected in Unit Units, enter a description								
f. Units Units (Required if Quantitative Limit is "Yes"); Select the correct limits units						<u>.</u>	The state of the s	
E Limit Quantity Quantity (Required if Quantitative Limit is "Yes"): Enter Limit Quantity								
D Quantitative Limit on Service? (Required if benefit is Covered): Select "Yes" if Quantitative Limit applies	NO	N.O	No.	SQ.	NG NO	No.	ę	No
C Benefit Description (Required if benefits Covered); Enter a Description, it may be the samg as the Benefit name	Transplants: autologous bone marrow transplant.	lood stem	asts.		Orthotics and prosthetics. Newborn hearing screening.		afment	of high levels of lead in blood. Mastectomy inpatient stay
Covered (Required): Is benefit Covered or Not Covered	Covered				Covered		Covered	Covered
AND T	Otter					Other C	Other	Other
Number	rd N		2		97	27	28	29

R Does this benefit have additional limitations or restrictions? (Required if benefit is Covered): Select "Yes," If there are additional limitations or restrictions or restrictions that need to be	described	ON	No	No	No	·	DN.
Enter an Explanation for anything not listed	equired. Surgery to restore and stry, and/or cost of prostheses stectomy on one or both breasts; hysical complications, including	nas, or self-management education and subseling as medically necessary; or insulin syringes and insulin needles; t strips; lancets; pumps and infusers,	Pria also	£	prescriptions when certain protocols are met, It is impermissible to require use of mail order only, it is impermissible to impose closed formularies,	o any administered ann-cancer prescription drugs No- must be covered on a basis at least as favorable as intravenously administered or injected anti-cancer medications.	Coverage is limited to demonstration of at least in one of the followings severe functional difficulties; developmental anomalies of facial bones and/or oral structure; facial trauma resulting in severe functional difficulties; or that psychological health requires orthodontic correction, Generally, requires orthodontic correction, Generally, deformittes, or functional difficulties in speach or mastication.
Exclusions (Optional): Enter any Exclusions for this benefit							Cosmetic orthodontla.
H Minimum Stay (Optional): Enter the Nintmum Stay (In hours) as a whole mumber							
G Other Limit Units Description (Required if "Other" Limit Unit): If a Limit Unit of "Other" was selected in Unit Units, enter a description							
timit tinits (Required if Quantitative Limit is "Yes"); Select the correct limits units							
E Limit Quantity (Required if Quantitative Limit is "Yos"!! Enter limit Quantity		-					
Quantitative Limit on Service? (Required if Penefit is Covered: Select "Yes" if Quantitotive Limit applies	Ó	9	o N	W.C.	NO NO	Q	<i>y</i>
C Benefit Description (Required if benefit is Covered): Enter a Description, it may be the same as the Benefit name		services and	nutritional counseling Prescription drugs — contraceptives (No	Prescription drugs — off label	Prescription drugs open formulary No and mail order restrictions Anti-cancer Prescription Drugs No	Orthodontia (per CHIP)	
Covered Covered Not Covered or Co	Dalawon		Covered	Covered	Covered	Covered	
Row A. Number Benefit			Other Other		Officer	Other	
Row Number			33	# #		37	

ı	V
	Ž
	RY AND CLASS
	\subseteq
	A
	>
	ö
	S BY CATEGORY AND CLA
. :	Ö
	>
	SENEFITS BY CATEGORY AN
	Ε
	핓
	Ÿ
1	LAN BE
	₹
ŧ	1
	쏫
	₹
1	≥
1	-DENCHM/
1	
ŗ	Ò
0	<u> </u>
ī	פרחם-10
(J
ï	9
Ċ	5
in M	2
. (2
CITUINITI	_
	<u>'</u>
Ĺ	Ď
-	قد.

L ANTI-INFLAMMATORY DRUGS ESICS, SHORT-ACTING ESICS, SHORT-CRAVING ONISTS ATION AGENTS E ANTI-INFLAMMATORY DRUGS E ANTI-INFLAMMATORY GARANTS E INFLAMODIFYING AGENTS E INFLAMODIFYING AGENTS E INHIBITORS E INHIBITORS E INHIBITORS ENTHER ENT	
DESTANCE ABUSE TREATMENT AGENTS DIPOID ANALGESICS, STORET-ACTING DOPOID ANALGESICS, STORET-ACTING DOPOID ANALGESICS, STORET-ACTING DOPOID ANALGESICS, STORET-ACTING DOPOID ANTAGONISTS ACCONDING GESSATION AGENTS BY	SUBMISSION COUNT
OFFICIAL AND CENTRAL ACTIONS OFFICIAL AND	20
I LOCAL ANESTHEIRS LOCAL ANESTHEIRS LOCAL ANESTHEIRS ALCOHOL DETERRINISANTI-CRAVING BETA-ACTAM BETA-ACTAM AMINOSITEROIDAL ANTI-INFLAMMATORY DRUGS AMINOSITEROIDAL ANTI-INFLAMMATORY ADUNCTS NO DRUM CHANNEL MODINGS TRUCTALCIA ANTI-CRAMMATORY DRUGS ANTI-CRAMMATORY DRUGS ANTI-CRAMMATORY DRUGS ANTI-CRAMMATORY ADUNCTS NO DRUG CLASS ANTI-CRAMMATORY DRUGTS ANTI-CRAMMATORY DRUGTS ANTI-CRAMMATORY DRUGTS REGOTONING CLASS NO DRUG CLASS NO DRUG CLASS NO DRUG CLASS REGOTONING CLASS NO DRUG CLASS REGOTONING CLASS NO DRUG CLASS REGOTONING CLASS NO DRUG CLASS NO DRUG CLASS REGOTONING CLASS NO DRUG CLASS NO DRUG CLASS REGOTONING CLASS NO DRUG CLASS NO DRUG CLASS NO DRUG CLASS REGOTONING CLASS NO DRUG CLASS NO DRUG CLASS NO DRUG CLASS NO DRUG CLASS REGOTONING CLASS NO DRUG CLASS REGOTONING CLASS NO DRUG CLASS REGOTONING CLASS REG	10
USCAL AMESTHERICS UCCHOL DETERRENTS/ANTI-CRAVING USDITANCE ABUSE TREATMENT AGENTS OPIOID BATIAGONISTS USDITANCE ABUSE TREATMENT AGENTS OPIOID BATIAGONISTS USDITANCE ABUSE TREATMENT AGENTS SWORKING CESSATION AGENTS USDITANCE ABUSE TREATMENT AGENTS SWORKING CESSATION AGENTS USDITANCE ABUSE TREATMENT AGENTS USDITANCE ABUSE TREATMENT OF THE RELATEDIAL ANTI-INFLAMMATORY DRUGS USDITANCE ABUSE TREATMENT OF THE RELATEDIAL ANTI-INFLAMMATORY DRUGS USDITANCE ABUSE TREATMENT OF THE RELATEDIAL AGENTS USDITANCE ABUSE TAKEN AGENTS USDITANCE ABUSE AGENTS USDITAN	6
ALCOHOL DETERRENTS/ANTI-CRAVING OPIOID ANTAGONISTS OPIOID CANDAGE OPIOID ANTAGONISTS OPIOID CANDAGE OPIOI	3
DESTANCE ABUSE TREATMENT AGENTS BESTANCE ABUSE TREATMENT AGENTS BY AGENTS RY AGENTS RAMINOGLYCOSIDES AMINOGLYCOSIDES AMINOGLYCOSIDES AMINOGLYCOSIDES AMINOGLYCOSIDES BETA-LACTAM, OTHER BETA-LACTAM, OTHER BETA-LACTAM, PENICILINS BETA-LACTAM, PENICILINS AMCROLIDES GUINOLOUSES SULFONAMIDES FETRACOCLURES ANTICONANIUSANTS, OTHER GALCIUM CHANNEL MODIFITING AGENTS GUINAL CHANNEL ROBIFITING AGENTS GUINAL CHANNEL RAGENTS CHOLINESTERASE INHBITORS TRICCLOS TRICCLO	, ,
SMOKING CESSATION AGENTS BULCOCORTICOIDS NONSTRENDEL ANT-INFLAMMATORY DRUGS AMIDISCACIOLA ANT-INFLAMMATORY DRUGS AMIDISCACIOLA ANT-INFLAMMATORY DRUGS AMIDISCACIOLA ANT-INFLAMMATORY DRUGS AMIDISCACIOLA ANT-INFLAMMATORY DRUGS BETA-LACTAM, CEPHALOSPORINS BETA-LACTAM, CEPHALOSPORINS BETA-LACTAM, PRICILLINS MACROLIDES QUINOLONES QUINOLONES SULFONAMIES ANTICONVULSANTS, OTHER GULTAMATE REDUCING AGENTS GULTAMATE REDUCING AGENTS GULTAMATE REDUCING AGENTS CHOLINESTERASE IN-HIBITORS FINTS ANTICORANIS OTHER MONDAMINE OXIDASE IN-HIBITORS FRICTICIS ANTICOLINS MONDAMINE OXIDASE IN-HIBITORS FRICTICIS ANTICOLINS ANTICOLINS MONDAMINE OXIDASE IN-HIBITORS FRICTICIS ANTICOLINS ANTICO	'n
BETA-LACTAM, CEPHALOSPORINS MONSTEROIDAL ANTH-INFLAMMATORY DRUGS AMINOGLYCOSIDES AMINOGLYCOSIDES AMINOGLYCOSIDES AMINOGLYCOSIDES AMINOGLONES BETA-LACTAM, OTHER BETA-LACTAM, PENICILINS MACACAULES AUTONAMINES TETRA-CYCLINES TETRA-CYCLINES ANTICONVULSANTS, OTHER GALIANNEL MODIFYING AGENTS GALIANARIE REDUCING AGENTS ANTIDEMENTIA AGENTS ANTIDEMENTA ANTIDEMENTIA AGENTS ANTIDEMEN	7
NAY AGENTS NONSTEROLIDAL ANTI-INELAMMATORY DRUGS AMINOGLYCOSIDES AMINOGLYCOSIDES BETA-LACTAM, CEPHALOSPORINS BETA-LACTAM, OTHER BETA-LACTAM, OTHER BETA-LACTAM, PENICILLINS MACROLIDES QUINOLONES SULFONAMINIDES TETRACYCLINES AMITODAVULISANTS, OTHER CALCIUM CHAINEL MODIFYING AGENTS GAMMAR-ANINOBUTYRIC GAD (GABA) AUGMENTING AGENTS GAMMAR-ANINOBUTYRIC GAD (GABA) AUGMENTING AGENTS GLUTAMATE REDICING AGENTS SODIUM CHAINEL AGENTS GLUTAMATE REDICING AGENTS GLUTAMATE CONTANEL REDICING AGENTS ANTIDERERESANTS, OTHER MONOAMINE ONTONE INHBITORS TRICYCLICS TRICYCLICS ANTIDERERESANTS, OTHER MONOAMINE ONTONE INHBITORS TRICKCLICS ANTIDERERESANTS, OTHER MONOAMINE ONTONE TRICKCLICS ANTIDERESANTS, OTHER MONOAMINE ONTONE TRICKCLICS ANTIDERERESANTS, OTHER MONOAMINE ONTONE TRICKCLICS TRICKCLICS TRICKCHICS	***
AMINOGLYCOSIDES ANTIBACTERIALS, OTHER BETA-LACTAM, DTHER BETA-LACTAM, PENCILINS BETA-LACTAM, PENCILINS BETA-LACTAM, PENCILINS MACROLIDES SULFONAMIES SULFONAMIES ANTICONVULSANTS, OTHER CALLUN CLANNEL MODIFYING AGENTS SODIUM CHANNEL MODIFYING AGENTS GLUTAMATE REDUCING AGENTS GLUTAMATE REDUCING AGENTS SODIUM CHANNEL AGENTS SODIUM CHANNEL AGENTS GLUTAMATE REDUCING AGENTS ANTIDEMENTA GRENTS ANTIDEMENTA GRENTS ANTIDEMENTA GRENTS SEROTONIN/NOREPINEPHRINE REUPTAKE INHIBITORS TRICYCLICS TRICYCLICS ANTIEMETICS, OTHER MOUSP CLASS NINTS ERGOT ALKALOIDS NINTS ERGOT ALKALOIDS NINTS ERGOT ALKALOIDS FINANCIALS FINANCIA	
ANTIBACTERIALS, OTHER BETA-LACTAM, CEPHALOSPORINS BETA-LACTAM, OTHER BETA-LACTAM, PENICILINS MACROLIDES QUINOLONES SULFONANIDES SULFONANIDES SULFONANIDES SULFONANIDES SULFONANIDES SULFONANIDES SULFONANIDES ANTIOCONULISANTS, OTHER CALCIUM CHANNEL MODIFYING AGENTS GAMMA-AMINOBUTYINC ACID (GABA) AUGMENTING AGENTS GAMMA-AMINOBUTYINC ACID (GABA) AUGMENTING AGENTS SULFONANIE MODIFYING AGENTS CHOLINESTERASE INHBITORS ANTIDERRESSANTS, OTHER MONDAMINE OXIDASE INHBITORS SEROTONIN/NOREPINEPHRINE REUPTAKE INHBITORS TRICYCLICS ANTIDERRESSANTS, OTHER MONDAMINE OXIDASE INHBITORS TRICYCLICS NO USP CLASS NOT USE CLASS NOT USE CLASS NATS REGOT ALKALOIDS NATS REGOT ALKALOIDS NATS REGOT ALKALOIDS	20
BETA-LACTAM, CEPPALOSPORINS BETA-LACTAM, OTHER BETA-LACTAM, OTHER BETA-LACTAM, OTHER BETA-LACTAM, PENICILINS MACROLIDES CULIONAROLIDES CULFONAROLIDES TETRACYCLINES ANTICONAVUISANTS, OTHER CALCINA CHAINEL MODIFYING AGENTS ANTICONAVUISANTS, OTHER CALCINA CANINA BUTTRIC ACID (GABA) AUGMENTING AGENTS GAMMA-AMINOBUTTRIC ACID (GABA) AUGMENTING AGENTS CALCINA CHAINEL MODIFYING AGENTS GALTAMA-TE REPUCING AGENTS SODIUM CHAINEL AGENTS ANTIDEMENTS, OTHER CHOLINESTERASE INHIBITORS NATIDEPRESSANTS, OTHER MONOAMINE REUPTAKE INHIBITORS TRICYCLICS ANTIDEPRESSANTS, OTHER MONOAMINE REUPTAKE INHIBITORS TRICYCLICS ANTIDEPRESSANTS, OTHER EMEROGENIC THERAPY ADJUNCTS NO USP CLASS NO USP CLASS BEROTORINA ARRADIOSE NATIONAL ARRADIOSE REGORD ARRADIOSE NATIONAL ARRADIOSE REGORD ARRADIOSE	9
BETA-LACTAM, OTHER BETA-LACTAM, OTHER BETA-LACTAM, OTHER BETA-CACTAM, PENICILINS MACROLIDES CAUINONAMIDES SULFONAMIDES TETRACYCLINES TETRACYCLINES ANTICONVULSANTS, OTHER CALCIUM CHANNEL MODIFYING AGENTS GAMMA-AMINOBUTRIC AGENTS GAMMA-AMINOBUTRIC AGENTS GALMAMA-AMINOBUTRIC AGENTS GALMAMTE REDUCING AGENTS GALMAMTE REDUCING AGENTS CHOLINESTERASE INHBITORS ANTIDEMENTIA AGENTS CHOLINESTERASE INHBITORS ANTIDEMENTIA AGENTS ANTIDEMENTIA AGENTS MONDARMINE GALMASE INHBITORS TRICYCLICS ANTIDEMENTICS, OTHER MONDAMINE ORDASE INHBITORS TRICYCLICS ANTIDEMENTICS, OTHER MONDAMINE GALMASE INHBITORS TRICYCLICS ANTIDEMENTICS, OTHER MONDAMINE GALMASE INHBITORS TRICYCLICS ANTIDEMENTICS, OTHER MONDAMINE GALMASE INHBITORS TRICYCLICS ANTIDEMENTICS, OTHER MONDAR CLASS NO USP CLASS NO USP CLASS NOTANIA ACCADIS TRICALINESTERASE TRICALINES	16
BETA-LACTAM, PENICILLINS MACROLIDES QUINOLONES QUINOLONES QUINOLONES SULFONAMIDES TETRACYCLINES ANTICONAMINE MODIFFING AGENTS GAMINA-AMINOBUTYRIC ACID (GABA) AUGMENTING AGENTS GULTAMATE REDUCING AGENTS GULTAMATE REDUCING AGENTS GODIUM CHANNEL AGENTS GODIUM CHANNEL AGENTS ANTIDEPRESSANTS, OTHER MONOAMINE OXIDASE INHIBITORS SEROTONIN/NOREPINEPHRINE REUPTAKE INHIBITORS TRICYCLICS ANTIEMETCS, OTHER MONOAMINE OXIDASE INHIBITORS TRICYCLICS ANTIEMETCS ANTIEME	12
MACTOGENIA, ENVELING QUINOLONES QUINOLONES QUINOLONES TETRACYCLINES ANTICONVULSANTS, OTHER GAMIMA-AMINOBUTYRIC ACID (GABA) AUGMENTING AGENTS GAMIMA-AMINOBUTYRIC ACID (GABA) AUGMENTING AGENTS GULTAMARE REDUCING AGENTS SODIUM CHANNEL AGENTS ANTIDEMERSASE INHIBITORS MANTIDEPRESSANTS, OTHER ANTIDEPRESSANTS, OTHER MONOAMINE OXIDASE INHIBITORS SEROTONIN/NOREPINEPHRINE REUPTAKE INHIBITORS TRICYCLICS ANTERFECT ANTERFACTOR ANTE	
QUINOLONES SULFONAMIDES TETRACYCLINES SULFONAMIDES TETRACYCLINES ANTICONVULSANTS, OTHER CALCIUM CHAINREL MODIFYING AGENTS GAMMA-AMINOBUTPRIC ACID (GABA) AUGMENTING AGENTS GLUTAMARTE REDUCING AGENTS SODIUM CHAINREL AGENTS ANTIDEMENTA AGENTS CHOLINESTERASE INHIBITORS ENTS CHOLINESTERASE INHIBITORS ANTIDEMESTERASE INHIBITORS ANTIDEMESTERASE INHIBITORS ANTIDEMESTERASE INHIBITORS SECTOONIN/NOREPINEPHRINE REUPTAKE INHIBITORS TRICYCLICS ANTIEMETICS, OTHER MONOAMINE OXIDASE INHIBITORS TRICYCLICS ANTIEMETICS, OTHER EMETOGENIC THERAPY ADJUNCTS NO USP CLASS NO USP CLAS	9
SULFONANDES FETRACYCLINES ANTICONVULSANTS, OTHER CALCIUM CHAINNEL MODIFYING AGENTS GAMMA-AMINOBUTYRIC ACID (CABA) AUGMENTING AGENTS GAMMA-AMINOBUTYRIC ACID (CABA) AUGMENTING AGENTS GALLIAMATE REDUCING AGENTS SODIUM CHANNEL AGENTS ANTIDEMENTIA AGENTS, OTHER CHOLINESTERASE INHIBITORS N-METHYL-D-ASPARTATE (IMIDA) RECEPTOR ANTAGONIST ANTIDEPRESSANTS, OTHER MONOAMINE OXIDASE INHIBITORS FRICYCLICS ANTIDEMENT REDUCINGS FRICYCLICS ANTIDEMENT REDUCINGS FRICYCLICS NO USP CLASS NO USP CLASS FRICYCLICS ANTIGENEL THERAPY ADJUNCTS NO USP CLASS FRICALICS FRICYCLICS NO USP CLASS FRICALICS FRICALICS NO USP CLASS FRICALICS FRICALICS FRICALICS NO USP CLASS FRICALICS FRI	4
TELEVICAMINES TELEVICAMINES ANTICONVULIASANTS, OTHER CALCIUM CHAINNEL MODIFYING AGENTS GAMINA-AMINOBUTYRIC ACID (GABA) AUGMENTING AGENTS GLUTAMATE REDUCING AGENTS GLUTAMATE REDUCING AGENTS SODIUM CHAINNEL AGENTS ANTIDEMENTIA AGENTS, OTHER CHOLINESTERASE INHIBITORS N-METHYLLD-ASPARTATE (NMDA) RECEPTOR ANTAGONIST ANTIDEPRESSANTS, OTHER MONOAMINE OXIDASE INHIBITORS TRICYCLICS ANTIEMETICS, OTHER EMETOGENIC THERAPY ADJUNCTS NO USP CLASS NO USP CLAS	80
ANTICONVUISANTS, OTHER ANTICONVUISANTS, OTHER GALCIUM CHANNEL MODIFYING AGENTS GAMMATE REDUCING AGENTS GULTAMATE REDUCING AGENTS GULTAMATE REDUCING AGENTS SODIUM CHANNEL AGENTS ANTIDEMENTA AGENTS ANTIDEPRESSANTS, OTHER MONOAMINE OXIDASE INHIBITORS TRICYCLICS ANTIEMETICS, OTHER MONOAMINE OXIDASE INHIBITORS TRICYCLICS ANTIEMETICS, OTHER MO USP CLASS NO USP CLASS	4
ANTICONVUISANTS, OTHER CALCIUM CHANNEL MODIPYING AGENTS GAMMA-AMINOBUTYRIC ACID (GABA) AUGMENTING AGENTS GLUTAMATE REDUCING AGENTS ENTS ENTS ENTS CHOLINESTERASE INHIBITORS N-METHYL-D-ASPARTATE (MMDA) RECEPTOR ANTAGONIST ANTIDEPRESSANTS, OTHER MONOAMINE OXIDASE INHIBITORS SEROTONIN/NOREPINEPHRINE REUPTAKE INHIBITORS TRICYCLICS ANTIEMETICS, OTHER EMETOGENIC THERAPY ADJUNCTS NO USP CLASS NO USP CLASS NO USP CLASS NO USP CLASS NATIONAL AGENCY MONOAMINE OXIDASE REGOT ALKAROIDS NATIONAL AGENCY NO USP CLASS NO USP CLASS NATIONAL AGENCY NO USP CLASS	4
GALCIUM CHANNEL MODIFYING AGENTS GAMMA-AMINOBUTYRIC ACID (GABA) AUGMENTING AGENTS GLUTAMATE REDUCING AGENTS SODIUM CHANNEL AGENTS ENTS ANTIDEMENTIA AGENTS, OTHER CHOLINESTERASE INHIBITORS N-METHYL-D-ASPARTATE (IMMDA) RECEPTOR ANTAGONIST ANTIDEPRESSANTS, OTHER MONOAMINE OXIDASE INHIBITORS SEROTONIN/NOREPINEPHRINE REUPTAKE INHIBITORS TRICYCLICS ANTIEMETICS, OTHER EMETOGENIC THERAPY ADJUNCTS NO USP CLASS NO USP CLASS NO USP CLASS NITS FROOT ALKAROIDS	C
GAMMA-AMINOBUTYRIC ACID (GABA) AUGMENTING AGENTS GLUTAMATE REDUCING AGENTS SODIUM CHANNEL AGENTS ENTS CHOLINESTERASE INHIBITORS ENTS CHOLINESTERASE INHIBITORS ANTIDEPRESSANTS, OTHER MONOAMINE OXIDASE INHIBITORS SEROTONIN/NOREPINEPHRINE REUPTAKE INHIBITORS TRICYCLICS ANTIEMETICS, OTHER EMETOGENIC THERAPY ADJUNCTS NO USP CLASS NTS REGOT ALKALOIDS NTS REGOT ALKALOIDS NTS REGOT ALKALOIDS NTS REGOT ALKALOIDS	7
SODIUM CHANNEL AGENTS	j 1
ENTS ENTS ANTIDEMENTIA AGENTS, OTHER CHOLINESTERASE INHIBITORS N-METHYL-D-ASPARTATE (NMDA) RECEPTOR ANTAGONIST ANTIDEPRESSANTS, OTHER MONDAMINE OXIDASE INHIBITORS SEROTONIN/NOREPINEPHRINE REUPTAKE INHIBITORS TRICYCLICS ANTIEMETICS, OTHER EMETOGENIC THERAPY ADJUNCTS NO USP CLASS	A
ENTS ANTIDEMENTIA AGENTS, OTHER ENIS CHOLINESTERASE INHIBITORS ENIS N-METHYL-D-ASPARTATE (NMDA) RECEPTOR ANTAGONIST ANTIDEPRESSANTS, OTHER MONOAMINE OXIDASE INHIBITORS SEROTONIN/NOREPINEPHRINE REUPTAKE INHIBITORS TRICYCLICS ANTIEMETICS, OTHER EMETOGENIC THERAPY ADJUNCTS NO USP CLASS NO USP CLASS NO USP CLASS NO USP CLASS NATS ERGOT ALKALOIDS	77
ENTS CHOLINESTERASE INHIBITORS N-METHYL-D-ASPARTATE (NMDA) RECEPTOR ANTAGONIST ANTIDEPRESSANTS, OTHER MONOAMINE OXIDASE INHIBITORS SEROTONIN/NOREPINEPHRINE REUPTAKE INHIBITORS TRICYCLICS ANTIEMETICS, OTHER EMETOGENIC THERAPY ADJUNCTS NO USP CLASS	Q
N-METHYL-D-ÁSPARTATE (NMDA) RECEPTOR ANTAGONIST ANTIDEPRESSANTS, OTHER MONOAMINE OXIDASE INHIBITORS SEROTONIN/NOREPINEPHRINE REUPTAKE INHIBITORS TRICYCLICS ANTIEMETICS, OTHER EMETOGENIC THERAPY ADJUNCTS NO USP CLASS NO USP CLASS REGOT ALKALOIDS	
ANTIDEPRESSANTS, OTHER MONOAMINE OXIDASE INHIBITORS SEROTONIN/NOREPINEPHRINE REUPTAKE INHIBITORS TRICYCLICS ANTIEMETICS, OTHER EMETOGENIC THERAPY ADJUNCTS NO USP CLASS INTS ERGOT ALKALOIDS	(Y)
MONDAMINE OXIDASE INHIBITORS SEROTONIN/NOREPINEPHRINE REUPTAKE INHIBITORS TRICYCLICS ANTIEMETICS, OTHER EMETOGENIC THERAPY ADJUNCTS NO USP CLASS NO USP CLASS ERGOT ALKALOIDS	-
SEROTONIN/NOREPINE REUPTAKE INHIBITORS TRICYCLICS ANTIEMETICS, OTHER EMETOGENIC THERAPY ADJUNCTS NO USP CLASS NO USP CLASS ERGOT ALKALOIDS	7
TRICYCLICS ANTIEMETICS, OTHER EMETOGENIC THERAPY ADJUNCTS NO USP CLASS NO USP CLASS ERGOT ALKALOIDS	4
ANTIEMETICS, OTHER EMETOGENIC THERAPY ADJUNCTS NO USP CLASS NO USP CLASS ERGOT ALKALOIDS	ā
EMETOGENIC THERAPY ADJUNCTS NO USP CLASS NO USP CLASS ERGOT ALKALOIDS	6
NO USP CLASS NO USP CLASS NO USP CLASS ERGOT ALKALOIDS	6
INTS ERGOT ALKALOIDS	10
INTS ERGOT ALKALOIDS	19
ERGOT ALKALOIDS	T T
50CF1103 8 CT170	n f
PRUPHILL	7
	'n

CATEGORY		
ANTIMIGRAINE AGENTS	CLASS	SUBMISSION COUNT
ANTIMYASTHENICAGENTS	SENCTIONIN (5-H1) 1B/1D RECEPTOR AGONISTS	7
ANTIMYCOBACTERIALS	PAKASYMPATHOMIMETICS	, r
ANTIMACODACTERIALS	ANTIMYCOBACTERIALS, OTHER	7
ANTIMODIACTOR	ANTITUBERCULARS	7
ANTINEONIACTION	ALKYLATING AGENTS	0.7
AINTINEOPLASTICS	ANTIANGIOGENIC AGENTS	Ŋ
ANTINEOPLASTICS	ANTIESTROGENS/MODIFIERS	2
ANTINEOPLASTICS	ANTIMETABOLITES	ന
ANTINEUPLASTICS	ANTINEOPIACTICS OTHER	· Parag
ANTINEOPLASTICS	AROMATASE INHIbitors and craims	2
ANTINEOPLASTICS	ENCYME INFIDENCES, SRD GENERALION	8
ANTINEOPLASTICS	MOLECIHAR TABGET MINITEDES	4
ANTINEOPLASTICS	MONOCIONAL ANTIDORICE	12
ANTINEOPLASTICS	RETINOING	0
ANTIPARASÍTICS	ANTHEIMINING	3
ANTIPARASITICS	ANTIPROTOZOAIS	3
ANTIPARASITICS	PENICH CIDEC CONTINUE	-
ANTIPARKINSON AGENTS	ANTICUOLINESCICE	Lej
ANTIPARKINSON AGENTS	ANTIDADVINISON ACTIVITY	2
ANTIPARKINSON AGENTS	DODAWINE ACCUMENTATION	3
ANTIPARKINSON AGENTS	DOEANINE AGUNIS IS	4
ANTIPARKINSON AGENTS	MONOAMINE PRECURSORS/L-AMINO ACID DECARBOXYLASE INHIBITORS	2
ANTIPSYCHOTICS	1ST GENERATION PUBLISHED	2
ANTIPSYCHOTICS	2011 GENEDATION/ATVEICAL	10
ANTIPSYCHOTICS	TREATMENT BESISTANT	6
ANTISPASTICITY AGENTS	NO 150 CLASS	T
ANTIVIRALS	ANTI-CYTOMEGALOWER (Chara comments)	m
ANTIVIRALS	ANTI UNI ACTATE NEW WILDS	7
The state of the s	INHIBITORS	V.
AINIVIKALS	ANTI-HIV AGENTS, NUCLEOSIDE AND NUCLEOTIDE REVERSE	A A
ANTINGOLO	TRANSCRIPTASE INHIBITORS	- 1
ANTIVIDALE	ANTI-HIV AGENTS, OTHER	
ANTHURALS	ANTI-HIV AGENTS, PROTEASE INHIBITORS	n
ANTHURALS	ANTI-INFLUENZA AGENTS	J
ANTIVIDALE	ANTIHEPATITIS AGENTS	4
ANTIVIRALS	ANTIHERPETIC AGENTS	12
ANNOUNTERS	ANXIOLYTICS, OTHER	LC.
ANAIOCETICS	SSRIS/SNRIS (SELECTIVE SEROTONIN REUPTAKE INHIBITORS/SEROTONIN	4 1
	AND NOREPINEPHRINE REUPTAKE INHIBITORS)	n

CATEGORY		
BIPOLAR AGENTS	BIDGLAD ACTURE CELES	SUBMISSION COUNT
BIPOLAR AGENTS	MOOD CTABLISTS	0
BLOOD GLUCOSE REGULATORS	MOUD 3 ABILICEKS	w
BLOOD GLUCOSE REGULATORS	ANTIDIABE II. AGENTS	55
BLOOD GLUCOSE REGULATORS	GET CENT AGENTS	2
BLOOD PRODUCTS/MODIFIERS/VOLUME EXPANDERS	ANTICACITANTE	10
BLOOD PRODUCTS/MODIFIERS/VOLUME EXPANDERS	BI OOD FORMATION MODIFIERS	5
BLOOD PRODUCTS/MODIFIERS/VOLUME EXPANDERS	COAGULANTS	8
BLOOD PRODUCTS/MODIFIERS/VOLUME EXPANDERS	PLATELET MODIFYING AGENTS	0
CARDIOVASCULAR AGENTS	ALPHA-ADRENERGIC AGONISTS	7
CARDIOVASCULAR AGENTS	ALPHA-ADRENERGIC BLOCKING AGENTS	3
CARDIOVASCULAR AGENTS	ANGIOTENSIN II RECEPTOR ANTAGONICTS	4
CARDIOVASCULAR AGENTS	ANGIOTENSIN-CONVERTING ENZYME (ACE) INCURPITORS	7
CARDIOVASCULAR AGENTS	ANTIARRHYTHMICS	10
CARLIJOVASCULAR AGENTS	BETA-ADRENERGIC BLOCKING AGENTS	6
CARDIOVASCULAR AGENTS	CALCIUM CHANNEL BLOCKING AGENTS	23
CARDIOVASCULAR AGENTS	CARDIOVASCII AR AGENTS OTHER	C
CARDIOVASCULAR AGENTS	DILIBETICS CABBONIC AMENDRASE SELECTION	7
CARDIOVASCULAR AGENTS	DIURETICS 1000	2
CARDIOVASCULAR AGENTS	DIIRFIICE POTACCI IM Chabing	.4
CARDIOVASCULAR AGENTS	DILIBETICE THINKING	7
CARDIOVASCULAR AGENTS	DYSI PIDEMICS FIRBLY ACTO DEDIVATIVES	9
CARDIQVASCULAR AGENTS	DYS(DIDENTS UNITS CAN REPLIES	2
CARDIOVASCULAR AGENTS	DYCIDIDENTICS OFFICE OF REDUCIASE INHIBITORS	7
CARDIOVASCULAR AGENTS	WASONI ATORS DIFFER A STREET	9
CARDIOVASCULAR AGENTS	VASCOLIATIONS, DIRECTACTING ARTERIAL	(r)
CENTRAL NERVOUS SYSTEM AGENTS	VASCUILATORS, DIRECT-ACTING ARTERIAL/VENOUS	*
	ALI FANTION DEFICIT HYPERACTIVITY DISORDER AGENTS, AMPHETAMINES	4
CENTRAL NERVOUS SYSTEM AGENTS	ATTENTION DEFICIT HYPERACTIVITY DISORDER AGENTS, NON-	7
CENTRAL NERVOUS SYSTEM AGENTS	CENTRAL MEDIANI RESIDENCE	
CENTRAL NERVOUS SYSTEM AGENTS	EIRDOMANALCIA ACTATE	4
CENTRAL NERVOUS SYSTEM AGENTS	MILITIDE COLEDANCE APPLIES	· C
DENTAL AND ORAL AGENTS	MO LIST OF KEE	
DERMATOLOGICAL AGENTS	INC. USE	9
ENZYME REPLACEMENT/AACHIECOS	NO USP CLASS	21
GASTROINTESTINAL AGENTS	NO USP CLASS	* C
GASTROINTESTINAL AGENTS	ANTISPASMODICS, GASTROINTESTINAL	A.
GASTROIMTECTINAL ACENTS	GASTROINTESTINAL AGENTS, OTHER	
INTERNITY ESTIMAL AGENTS	HISTAMINE2 (H2) RECEPTOR ANTAGONISTS	0
		→

CATEGORY	AND M.	
GASTROINTESTINAL AGENTS		SUBMISSION COUNT
GASTROINTESTINAL AGENTS	INKLIABLE BUWEL SYNDROME AGENTS	7
GASTROINTESTINALACENITS	LAXATIVES	ır
A STROUNTERSTAIN A DESCRIPTION OF THE PROPERTY	PROTECTANTS	n
CASINOLINES INVALAGEN IS	PROTON PUMP INHIBITORS	2
GENTI OURINARY AGENTS	ANTISPASMODICS LIRINARY	ė
GENITOURINARY AGENTS	BENIGN PROSTATIC HYDERTROBUN ACENITE	7
GENITOURINARY AGENTS	GEMITOLIBINADY ACTIVITY CALLER	o,
GENITOURINARY AGENTS	DHOGOLATE DINNERS	83
HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING	GLUCOCORTICOLDS/MINIEDALOCORTICOLOS	8
(ADRENAL)		23
HURINONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING (PITUITARY)	NO USP CLASS	4
HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING	NO USP CLASS	**
HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING (SEX	ANABOLIC STEROIDS	₩.
HORMONAL AGENTS, STIMULANT/REPI ACEMENT/AAODIEVING 1657	7 1 1 2 C C C C C C C C C C C C C C C C C	73
HORMONES/MODIFIERS)	ANDROGENS	T T
HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING (SEX HORMONES/MODIFIERS)	ESTROGENS	9
HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING (SEX	PROGESTINS	•
HORMONES/MODIFIERS)		'n
HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIEYING (SEX HORMONES/MODIFIERS)	SELECTIVE ESTROGEN RECEPTOR MODIFYING AGENTS	
HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING	NO USP CLASS	
HORMONAL AGENTS SUPPLESSANT ASSESSMENT		ÖĞ
HORMONA' ACTIVITY FILESCOOL SALES	NO USP CLASS	
HODANGNAL AGENTS, SUPPRESSANT (PARATHYROID)	NO USP CLASS	The state of the s
HOBINOMAL AGENTS, SUPPRESSANT (PITUITARY)	NO USP CLASS	-1 -
HORMONAL AGENTS: SUPPRESSANT (SEX HORMONES/MODIFIERS)	ANTIANDROGENS	χ.
MAMINING OCIVE ACENTE	ANTITHYROID AGENTS	
MAMINOLOGICAL ACENTS	IMMUNE SUPPRESSANTS	۲ مرث
MANATALIST COLOR AGENTS	IMMUNIZING AGENTS, PASSIVE	Te
IMIMUNOLOGICAL AGENTS	IMMUNOMODULATORS	0
INFLAMMATORY BOWEL DISEASE AGENTS	AMINOSALICYLATES	8
INFLAMMAIORY BOWEL DISEASE AGENTS	GLUCOCORTICOIDS	77
INFLATIONAL URY BOWEL DISEASE AGENTS	SULFONAMIDES	
IVIETABOLIC BONE DISEASE AGENTS	NO USP CLASS	
OPHI HALMIC AGENTS	OPHTHALMIC PROSTAGI ANDIN AND PROCTAGAINE ANALOGE	
OPHTHALMIC AGENTS	OPHTHALMIC AGENTS. OTHER	33
The state of the s	And the second s	**

New Jersey—1

CATEGORY		
OBHTHAI MIC ACENTS	CLASS	SUBMISSION COLINT
	OPHTHALMIC ANTI-ALLERGY AGENTS	
OPPLICACENIS	OPHTHALMICANTI-INFLAMMATORIFC	'n
OPHTHALMIC AGENTS	OPHTHALMIC ANTIGIALICOMA AGENTS	
OTICAGENTS	NO ICE CLACE	14
RESPIRATORY TRACT AGENTS	ANTI-INE AMANATORIES INVISES	9
RESPIRATORY TRACT AGENTS	ANTI-LISTAN MINTES, INFIALED CORTICOSTEROIDS	9
RESPIRATIORY TRACT AGENTS	ANTH DIVIDENCES	6
RESPIRATORY TRACT AGENTS	AINTITEONOLKIENES	
DECOIDATORYTOACT	BRONCHODILATORS, ANTICHOLINERGIC	
MISTINATORI TRACI AGENTS	BRONCHODILATORS, PHOSPHONIFSTERAGE INMINITARIE / ANNIETTERAGE	7
RESPIRATORY TRACT AGENTS	BRONCHONI ATORE CVARDATION AND ATORES	2
RESPIRATORY TRACT AGENTS	MART CELL ETABLISTER	10
RESPIRATORY TRACT AGENTS	MASS CITE STABILIZERS	T
BESDIBATORY TO ACT ACENTO	FULMUNARY AN IIHYPERTENSIVES	7
OLUMBIA SECTIONAL SECTIONA	RESPIRATORY TRACT AGENTS, OTHER	+
Sheld AL MUSCLE RELAXANTS	NO USP CLASS	4
SLEEP DISORDER AGENTS	GABA RECEPTOR MODILI ATORS	Q
SLEEP DISORDER AGENTS	STEED DISCORDED OFFICE	רוז
THERAPEUTIC NUTRIENTS/MINERALS/ELECTROLYTES	LITTING LITTING	S.
THERAPEUTIC NUTRIENTS/MINERALS/FLECTROLYTES	CLECTROLITE/WINERAL MODIFIERS	9
	GLECTROLLY IE/MINERAL REPLACEMENT	5
	The state of the s	

Exhibit B

Johnson, Eric D.

From:

Johnson, Eric D.

Sent:

Wednesday, August 06, 2014 9:28 AM

To:

Robinson, Mark E.

Subject:

RE: \$50 Copay for Chirporactic Services - DOBI File 200477 - Matlock Family

Chiropractic

Attachments:

NJ Ther Analysis (6 Svc Codes) (PP MBR LIA = 0) xlsx

See the attached...

From: Robinson, Mark E.

Sent: Tuesday, August 05, 2014 2:49 PM

To: Johnson, Eric D.

Subject: RE: \$50 Copay for Chirporactic Services - DOBI File 200477 - Matlock Family Chiropractic

Eric:

Thank you for both of the new calculations. While I'm confident that the latest calculation producing \$93.69 is likely correct, I'm interested in more insight about the claims for which Deductible, Coinsurance and Copay are all = 0. The claims like this must have a greater average allowed amount per visit. Can you produce distributions of the allowed costs for these claims 1) by service type code and 2) by servicing provider specialty code/description. Mostly, I'm curious why no cost sharing appears to have applied. We could also look at it by procedure code, but I don't want to start with that detail.

On a separate thought, do the new calculations include the month of July 2014 posted claims? If so, we could consider including dates of service through 6/30/2014. While we may prefer to be consistent with the original basis, I am open to including a later month (particularly if we ever get back over \$100). Thanks,

Mark

From: Johnson, Eric D.

Sent: Tuesday, August 05, 2014 11:27 AM

To: Robinson, Mark E.

Subject: FW: \$50 Copay for Chirporactic Services - DOBI File 200477 - Matlock Family Chiropractic

Hi Mark,

Bad news.

By excluding claims where both Deductible = 0 and Coinsurance = 0, I was still capturing claims where there was no member liability (claims where Deductible, Coinsurance, and Copay all = 0). I confirmed that I was pulling claims with no member liability.

After revising the query to only look at claims where COPAY > 0 (only claims subject to a copay), the analysis now has 81,883 service counts and a \$90.68 allowed cost per visit for 2018; and 40,084 service counts and a \$93.69 allowed average cost per visit for 2014.

I renamed the revised files to reflect the filter used.

NJ Ther Analysis (6 Svc Codes) (PP No DED or COI) xisk

MJ Ther Analysis (6 Svc Codes) (PP Copay Only), xlsx

From: Johnson, Eric D.

Sent: Tuesday, August 05, 2014 10:49 AM

To: Robinson, Mark E.

Subject: RE: \$50 Copay for Chirporactic Services - DOBI File 200477 - Matlock Family Chiropractic

HI Mark,

You door has been closed all morning, however, I believe I understood the request and revised the query accordingly.

The original analysis had 111,407 service counts and a \$94.43 allowed cost per visit for 2013; and 54,404 service counts and a \$100.70 allowed average cost per visit for 2014.

The revised (copay only) analysis has 106,519 service counts and a \$94.69 allowed cost per visit for 2013; and 51,218 service counts and a \$100.89 allowed average cost per visit for 2014.

The revised file is named "NJ Ther Analysis (6 Svc Codes) (PP Copay Only)."

From: Robinson, Mark E.

Sent: Tuesday, August 05, 2014 9:02 AM

To: Johnson, Eric D.

Subject: FW: \$50 Copay for Chirporactic Services - DOBI File 200477 - Matlock Family Chiropractic Importance: High

Strain Strain Eric;

> Please see Gale Simon's latest request, below, and evaluate. Let's briefly discuss this (maybe 10:00 AM?), before you go far with an analysis. Thanks,

Mark

From: Simon, Gale [mailto:Gale:Simon@dobi:state.nj.us]

Sent: Monday, July 28, 2014 1:15 PM

To: Robinson, Mark E.: Vance, Neil: DeRosa, Ellen

Cc: Martino, Peg; Pilgrim, Yvonne: Tallaferro Jr., Lilton R.

Subject: RE: \$50 Copay for Chirporactic Services - DOBI File 200477 - Matlock Family Chiropractic

Mark, I hate to be a pest but the demonstration should only include network chiropractic, OT, PT and ST services to which a network copay was applied. If there are any such dialms that were subject to a network deductible and/or a network coinsurance, those claims should not be included.

Can you have the demonstration revised accordingly?

Thanks.

From: Robinson, Mark E. [mailto:Mark E. Robinson@ibx.com]

Sent: Friday, July 25, 2014 5:17 PM

To: Simon, Gale, Vance, Neil; DeRosa, Ellen

Cc: Martino, Peg; Pilgrim, Yvonne; Taliaferro Jr., Lilton R.

Subject: RE: \$50 Copay for Chirporactic Services - DOBI File 200477 - Matlock Family Chiropractic

As a follow-up to the phone meeting on Wednesday, we revised the demonstration again to only include network services of chiropractic care, physical therapy, occupational therapy and speech therapy (no longer including cardiac rehabilitation, pulmonary rehabilitation and infusion therapy). For these services, AmeriHealth's fully-insured claims paid year-to-date with 1/1/2014 through 5/31/2014 dates of service included 54,404 provider visits at an aggregate provider allowance of \$5,478,326. These claims averaged a \$100.70 allowed cost per visit. Thus, the referenced copay of \$50 represents 49.7% of the aggregate risk of these services; Sincerely,

Mark E. Robinson, ASA, MAAA Independence Blue Cross Family of Companies (215) 241-2215 Mark E. Robinson@ibx.com

From: Simon, Gale [mailto:Gale,Simon@dobi.state.nj.us]

Sent: Wednesday, July 23, 2014 10:26 AM

To: Robinson, Mark E.; Vance, Nell, DeRosa, Ellen

Cc: Martino, Peg: Pilgrim, Yvonne; Taliaferro Jr., Lilton R.

Subject: RE: \$50 Copay for Chirporactic Services - DOBI File 200477 - Matlock Family Chiropractic

Mark, Ellen and I have questions about the demonstration, specifically about why I, S and C codes are included as well as services rendered by medical doctors and hospitals. Do you have any time for a call today or should we raise our questions in the Thursday call?

Thanks.

From: Robinson, Mark E. [mailto:Mark E. Robinson@ibx.com]

Sent: Tuesday, July 22, 2014 7:33 PM

To: Simon, Gale; Vance, Neil

Cc: Martino, Peg; Pilgrim, Yvonne; Taliaferro Jr., Lilton R.

Subject: RE: \$50 Copay for Chirporactic Services - DOBI File 200477 - Matlock Family Chiropractic

We revised the original reporting methodology to exclude the amounts for out-of-network services. Limited to network services, Ameritealth's fully insured the apeutic manipulations and therapy services claims paid year-to-date with 1/1/2014 through 5/31/2014 dates of service included 67,042 provider visits at an aggregate provider allowance of \$9,915,429. These claims averaged a \$147.90 allowed cost per visit. Thus, the referenced copay of \$50 represents 33.8% of the aggregate risk of these services. Sincerely,

Mark E. Robinson, ASA, MAAA Independence Blue Cross Family of Companies (215) 241-2215 Mark E. Robinson @ibx.com

From: Simon, Gale [mailto:Gale.Simon@dobi.state.nj.us]

Sent: Thursday, July 17, 2014 8:22 AM
To: Robinson, Mark E.; Vance, Neil

Cc: Martino, Peg; Pilgrim, Yvonne; Taliaferro Jr., Lilton R.

Subject: RE: \$50 Copay for Chirporactic Services - DOBI File 200477 - Matigck Family

Chiropra & c

I omitted a word - you can't include the amounts for out of network services...

From: Simon, Gale

Sent: Wednesday, July 16, 2014 7:35 PM
To: 'Mark, E. Robinson@lbx, com'; Vance, Neil

Cc: Martino, Peg; 'Yvonne, Pilgrim@ibx.com'; 'lilton.taliaferro@ibx.com'

Subject: Re: \$50 Copay for Chirporactic Services - DOBI File 200477 - Matlock Family

Chiropractic

Mark, you can't <u>include</u> the amounts for out of network services as the test is for a network copay so should include only the allowed amount for network services. Please omit the out of network services and tell me what those numbers are

From: Robinson, Mark E. [mailto:Mark E. Robinson@ibx.com]

Sent: Wednesday, July 16, 2014 06:58 PM

To: Simon, Gale; Vance, Nell

Cc: Martino, Peg; Pilgrim, Yvonne < Yvonne.Pilgrim@ibx.com>; Taliafeiro Jr., Lilton R.

<Lilton.Taliaferro@lbx.com>

Subject: RE: \$50 Copay for Chirporactic Services - DOBI File 200477 - Matlock Family

Chiropractic

Attached is a list of the procedure codes (CPT or HCPCS) included in the analysis, shown in decreasing order of the proportion of overall allowed costs included in the analysis. Please note that inclusion of claims in the analysis was not determined solely based on procedure codes. Instead, a combination of service type codes (derived within AmeriHealth's data warehouse) and procedure codes was used to identify the included claims.

The provider types who submitted the claims were physical therapy (44.6% of allowed costs), occupational or speech therapy (2.6%), chiropractic (12.0%), hospital (mostly infusion therapy; 13.8%), other therapy (15.3%), medical doctor (5.7%), home health (3.6%), cardiac rehabilitation (1.5%) and others (0.9%).

Claims included in the analysis were those for both participating and non-participating providers. Sincerely,

Mark E. Robinson, ASA, MAAA Independence Blue Cross Family of Companies (215) 241-2215 Mark E. Robinson@ibx.com

From: Simon, Gale [mailto:Gale.Simon@dobi.state:ni.us]

Sent: Monday, July 07, 2014 10:08 AM To: Robinson, Mark E.; Vance, Nell

eriom i de la fille de la propertación de la companya de la companya de la companya de la companya de la compa

Cc: Martino, Peg; Pilgrim, Yvonne; Tallaferro Jr., Lilton R.

Subject: RE: \$50 Copay for Chirporactic Services - DOBI File 200477 - Matlock Family Chiropractic

Please provide a list of the CPT codes included in your analysis and identify the provider types who submitted the claims, e.g. medical doctors, chiropractors, physical therapists, etc. Also please confirm that these are network providers only.

Thank you.

From: Robinson, Mark E. [mailto:Mark.E.Robinson@lbx.com]

Sent: Thursday, July 03, 2014 4:02 PM

To: Simon, Gale; Vance, Neil

Cc: Martino, Peg; Pilgrim, Yvonne; Taliaferró Jr., Lilton R.

Subject: RE: \$50 Copay for Chirporactic Services - DOBI File 200477 - Matlock Family

Chiropractic

AmeriHealth has interpreted N.J.A.C. 11:22-5.5(a)11 to require that the copayment applicable to therapeutic manipulations and therapy services is on average less than 50% of the aggregate risk of these services. For demonstration of compliance, AmeriHealth's fully-insured therapeutic manipulations and therapy services claims paid year-to-date with 1/1/2014 through 5/31/2014 dates of service have included 77,331 provider visits at an aggregate provider allowance of \$11,943,735. These claims averaged a \$154.45 allowed cost per visit. Thus, the referenced copay of \$50 represents 32.4% of the aggregate risk of these services. Sincerely,

Mark E. Robinson, ASA, MAAA Independence Blue Cross Family of Companies (215) 241-2215 Mark E. Robinson@ibx.com

Exhibit C

Johnson, Eric D.

From:

Robinson, Mark E.

Sent:

Friday, June 27, 2014 1:35 PM

To:

Johnson, Eric D.

Subject:

FW: Therapy Services

3 of 3

From: Forman, Beth

Sent: Friday, June 20, 2014 9:06 AM

To: Robinson, Mark E.

Subject: FW: Therapy Services

2 of 2

From: Alvarado, Rebecca

Sent: Monday, July 11, 2011 11:38 AM

To: Forman, Beth

Subject: RE: Therapy Services

Beth,

I updated the file so that it now includes all the categories based on your suggestion below. We meet the 50% requirement in aggregate, but some of the individual service type do not meet the requirement independently. Here is a link to the file:

\\g3\actuary\AMERIHLT\NJ\RATE_FIL\Minimum Standard Benefits\data.xlsx <file:///\\g3\actuary\AMERIHLT\NJ\RATE_FIL\Minimum%20Standard%20Benefits\data.xlsx>

Becky Alvarado

Small Group Pricing

Independence Blue Cross

(215) 241-9141

1

INTERNAL IBC DOCUMENTA

THIS DOCUMENT MAY NOT BE FORWARDED TO ANYONE THAT IS NOT AN ASSOCIATE OF THE INDEPENDENCE BLUE CROSS FAMILY OF COMPANIES.

From: Forman, Beth

Sent: Friday, July 08, 2011 11:21 AM

To: Alvarado, Rebecca

Subject: RE: Therapy Services

Hi Becky -

Great – thanks. On the summary tab, can you also show cost/claim (in addition to cost/unit?). I think this will be more meaningful. If you have a chance, can you also spend a few minutes flipping through the CPT manual (outside of Carolyn's office) & see if you can add in a few of the others? I did a quick search on-line & came up with the following:

1) Chemotherapy codes

http://www.bcbsks.com/customerservice/providers/Publications/institutional/manuals/workshop/AllPayers 07/BlueCross HCPCS update.pdf

2) Cardiac Rehab:

93797; 93798

 $\frac{http://medpolicy.ibx.com/policies/MPI.nsf/6eeddf656d983ec98525695e0068df68/85256aa800623d7a8525677004b2339!OpenDocument&Highlight=0, cardiac, rehab$

3) Pulmonary Rehab (maybe we can try the codes listed under the HCPCS2 section?)

http://medpolicy.ibx.com/policies/MPI.nsf/6eeddf656d983ec98525695e0068df68/85256aa800623d7a852576dd005e62b31OpenDocument&Highlight=0,pulmonary

4) Cognitive therapy (from Medicare website)

Question 7: Is there a specific HCPCS code or range of HCPCS codes to report for cognitive speech therapy training?

Answer: For cognitive speech therapy, a speech-language pathologist could use either code [CPT] 92507

Exhibit D

New Jersey Fully-Insured Commercial Therapeutic Svcs 6 Svc Codes*

		Average		
Month	SVCs	Plan Liability	MBR Liability	Allowed Cost
201301	6,995	61.61	30.54	92.15
201302	6,416	56.63	30.85	87.48
201303	6,874	56,68	31.29	87.97
201304	7,312	59.12	31.06	90.18
201305	7,458	55.35	31.06	86.41
201306	5,289	54.32	30.81	85.13
201307	7,371	60.58	29.65	90.23
201308	6,885	64.76	29.37	94.13
201309	6,153	64,98	30.55	95.54
201310	7,200	63.07	30.64	93.71
201311	6,574	60.23	30,32	90.55
201312	6,356	65.23	29.93	95.16
CY 2013	81,883	60.18	30.51	90.68
201401	7,890	68,93	30.92	99.85
201402	7,791	63,54	30.53	94.08
201403	8,268	59.24	33.10	92,33
201404	8,346	57.77	32,94	90.71
201405	7,789	58.90	32,79	91.69
2014 to Date	40,084	61.61	32,08	93.69

^{*}Includes all line items of claims containing at least one line item among the following service types:

Svcs Code	Description
2034	OCCUPATIONAL/SPEECH THERAPY
2035	PHYSICAL THERAPY
2037	CHIROPRACTIC
3034	OCCUPATIONAL/SPEECH THERAPY
3035	PHYSICAL THERAPY
3037	CHIROPRACTIC

Exhibit E

Johnson, Eric D.

From:

Robinson, Mark E.

Sent:

Friday, August 08, 2014 9:32 AM

To:

Johnson, Eric D.

Subject:

RE: \$50 Copay for Chirporactic Services - DOBI File 200477 - Matlock Family

Chiropractic

Eric:

I figured you would be surprised by this. It was intentional and not the result of any confusion about the different calculation scenarios. Let's fully discuss during our 10:00 AM meeting,

Mark

From: Johnson, Eric D.

Sent: Friday, August 08, 2014 9:28 AM

To: Robinson, Mark E.

Subject: RE: \$50 Copay for Chirporactic Services - DOBI File 200477 - Matlock Family Chiropractic

Hi Mark,

I am confused as to why we responded with the \$100.89 amount as opposed to the \$94 amount (when also excluding claims where member liability = 0 from the data).

I thought that Cindy's analysis of claims where member liability = 0 revealed scenarios where the plandesign was a 100% plan coinsurance or the member reached their OOP Max (plan design switched to a 100% plan coinsurance).

My thinking is that given the above, these scenarios (member liability = 0) also have no network copay applied (much like deductible / coinsurance scenarios) and should be excluded from the data resulting in the \$94 average cost per visit.

From: Robinson, Mark E.

Sent: Thursday, August 07, 2014 7:46 PM

To: Janney, John R.; Johnson, Eric D.; Lakshman, Hugh; Munoz, Michael A.; Petrizzi, Ryan J.; Rachfalski,

Daniel

Cc: Taliaferro Jr., Lilton R.

Subject: FW: \$50 Copay for Chirporactic Services - DOBI File 200477 - Matlock Family Chiropractic

Exhibit F

2014 NJ Copay Fraud Damages

Metal Level	HIOS ID	Chiro/PT/ST/OT Copay	Cost Share Reduction	<u>Reinsurance</u>	Premium <u>Subsidy</u>
Bronze ON-X	91762NJ0070004-01	75		3,012,268	TBD
Bronze OFF-X	91762NJ0070007-00	75		818,948	
Silver ON-X	91762NJ0070005-01	75		159,946	TBD
Silver OFF-X	91762NJ0070063-00	75		119,521	
Silver 73 CSR	91762NJ0070005-04	75	138	204,310	157,442
Silver 87 CSR	91762NJ0070005-05	60	161,018	643,924	377,746
Silver 94 CSR	91762NJ0070005-06	30	159,662	488,832	201,973
Silver ON-X	91762NJ0070006-01	75		129,346	
Silver OFF-X	91762NJ0070064-00	75		o n	
Silver 73 CSR	91762NJ0070006-04	75	0	0	300,135
Silver 87 CSR	91762NJ0070006-05	60	173,494	461,832	752,933
Silver 94 CSR	91762NJ0070006-06	30	243,174	488,833	525,129
Silver ON-X	91762NJ0070007-01	75		1,967,359	TBD
Silver OFF-X	91762NJ0070065-00	75		429,500	
Silver 73 CSR	91762NJ0070007-04	60	**************************************	2,273,195	5,061,887
Silver 87 CSR	91762NJ0070007-05	40	1,817,202	5,811,940	13,747,887
Silver 94 CSR	91762NJ0070007-06	30	2,926,776	4,153,568	9,631,655
Silver ON-X	77606NJ0040001-01	75		1,097,423	TBD
Silver OFF-X	77606NJ0040051-00	75		110,981	,00
Silver 73 CSR	77606NJ0040001-04	75 75	122,899	943,766	2,124,632
Silver 87 CSR	77606NJ0040001-05	60	1,490,903	2,494,807	5,521,492
Silver 94 CSR	77606NJ0040001-06	30	1,203,107	1,042,726	2,722,365
Gold ON-X	91762NJ0070010-01	50		1,896,373	TBD
Gold OFF-X	91762NJ0070067-00	50		1,594,776	100
		Total Option 1	8,298,373	30,344,174	41,125,273

2015 NJ Copay Fraud Damages

<u>Metal Level</u>	HIOS ID	Chiro/PT/ST/OT Copay	Cost Share Reduction	Reinsurance	Premium Subsidy	
			200 T STATE (1800 ST			
Bronze ON-X	91762NJ0070004-01	75		1,045,211	TBD	
Bronze OFF-X	91762NJ0070004-00	75		179,283	and the second s	
Bronze ON-X	91762NJ0070081-01	75		272,907		
Bronze OFF-X	91762NJ0070081-00	75				
Silver ON-X	91762NJ0070008-01	75		1,759,818	TBD	
Silver OFF-X	91762NJ0070008-00	75		0 🖔		
Silver 73 CSR	91762NJ0070008-04	75	126,094	403,284	1,040,903	
Silver 87 CSR	91762NJ0070008-05	60	869,468	2,052,984	2,195,422	
Silver 94 CSR	91762NJ0070008-06	30	962,196	1,319,658	1,016,692	
Silver ON-X	91762NJ0070006-01	75		159,886		
Silver OFF-X	91762NJ0070006-00	75		7,943		
Silver 73 CSR	91762NJ0070006-04	75	15,927	200,529	166,219	
Silver 87 CSR	91762NJ0070006-05	60	248,675	399,011	433,991	
Silver 94 CSR	91762NJ0070006-06	30	222,903	151,089	258,879	
Silver ON-X	91762NJ0070007-01	75		1,369,281	TBD	
Silver OFF-X	91762NJ0070007-00	75		476,504		
Silver 73 CSR	91762NJ0070007-04	60	317,410	867,432	2,521,332	
Silver 87 CSR	91762NJ0070007-05	40	4,408,681	2,224,611	6,626,488	
Silver 94 CSR	91762NJ0070007-06	30	3,984,762	1,432,371	4,317,336	
Silver ON-X	77606NJ0040001-01	75		338,022	TBD	
Silver OFF-X	77606NJ0040001-00	75		256,038		
Silver 73 CSR	77606NJ0040001-04	75	90,008	207,699	1,334,763	
Silver 87 CSR	77606NJ0040001-05	60	955,444	643,729	3,056,118	
Silver 94 CSR	77606NJ0040001-06	30	846,803	521,833	1,536,027	
		Total Option 1	13,048,371	16,289,123	24,504,167	

		Cost Share Reduction	Reinsurance	Premium <u>Subsidy</u>	
	2014 HIOS ID				
1	91762NJ0070004	0	3,831,216	0	
2	91762NJ0070005	320,818	1,616,533	737,160	
3	91762NJ0070006	416,668	1,080,011	1,578,196	
4	91762NJ0070007	4,743,978	14,635,562	28,441,428	
5	77606NJ0040001	2,816,909	5,689,703	10,368,489	
6	91762NJ0070010	0	3,491,149	0	
	2014Total	8,298,373	30,344,174	41,125,273	79,767,820
				_	· · · · · · · · · · · · · · · · · · ·
	2015 HIOS ID				
1	91762NJ0070004	0	1,224,494	0	
2	91 7 62NJ0070081	0	272,907	0	
3	91762NJ0070008	1,957,758	5,535,744	4,253,017	
4	91762NJ0070006	487,505	918,458	859,088	
5	91762NJ0070007	8,710,853	6,370,199	13,465,156	
6	77606NJ0040001	1,892,255	1,967,321	5,926,908	
	2015 Total	13,048,371	16,289,123	24,504,167	53,841,661

Exhibit G

Order No. E15- 106

STATE OF NEW JERSEY DEPARTMENT OF BANKING AND INSURANCE

IN THE MATTER OF:

Proceedings by the Commissioner of Banking and Insurance to Fine Freelancers Consumer Operated and Oriented Program of New Jersey,	Ś	CONSENT ORDER
abararaa ana Oriotton I toktatii of MeM Jelle's'	inc.)	

TO: Freelancers Consumer Operated and Oriented Program of New Jersey, Inc. 570 Broadway, Suite 1100 Newark, NJ 07102

This matter having been opened by the Commissioner of the Department of Banking and Insurance ("Commissioner"), State of New Jersey, upon information that Freelancers Consumer Operated and Oriented Program of New Jersey, Inc. ("Freelancers"), doing business as Health Republic Insurance of New Jersey, has violated provisions of the laws of the State of New Jersey; and

WHEREAS, Freelancers is a domestic insurance company authorized to transact business in New Jersey pursuant to N.J.S.A. 17B:18-42 since May 1, 2013; and

WHEREAS, N.J.A.C. 11:22-5.9(b)3 requires that the most preferred tier of a drug formulary, i.e. the tier with the lowest cost sharing, include more than one drug to treat each covered disease state where more than one drug is available; and

WHEREAS, N.J.A.C. 11:22-5.5(a) caps copayments for specified network services such as primary care and specialist physician visits and provides that for services not specified, the network copayment must be determined so that the carrier insures 50% or more of the aggregate risk for the service or supply to which the copayment is applied; and

WHEREAS, N.J.S.A. 26:2S-4 provides that a carrier shall disclose in writing to a subscriber, at the time of enrollment, among other things, a description of the covered services and benefits to which the subscriber or other covered person is entitled, the restrictions or limitations on covered services and benefits, the financial responsibility of the covered person, including copayment and deductibles, prior authorization and any other review requirements with respect to accessing covered services, where and in what manner covered services may be obtained, the covered person's right to appeal and the procedure for initiating an appeal of a utilization management decision made by or on behalf of the carrier with respect to the denial, reduction or termination of a health care benefit or the denial of payment for a health care service, and the procedure to initiate an appeal through the Independent Health Care Appeals Program; and

WHEREAS, N.J.A.C. 11:24A-2.3 provides that carriers shall provide to each subscriber within no more than 30 days following the effective date of coverage, through a handbook, certificate or other evidence of coverage, information describing, among other things, the covered services under the policy or contract including all exclusions, limitations, restrictions on accessing covered services such as prior authorization, preadmission certification and periodic review of ongoing treatment, a full and clear description of the carrier's policies and procedures for the provision of emergency and urgent care services, all dollar, day, visit or procedure limits and the method of exchanging inpatient for outpatient services, the responsibility of the covered person to pay deductibles, coinsurance or copayment as appropriate, and where and in what manner covered services can be obtained; and

WHEREAS, N.J.A.C. 11:4-37.3(b)3 provides that a carrier shall provide each covered person with a current evidence of coverage within 30 days of enrollment and no later than 30 days after any policy or contract changes; and

WHEREAS, N.J.A.C. 11:22-3.3(c) specifies that the paper standard format for the standard health care enrollment form for health insurance coverage can be accessed at http://www.state.nj.us/dobi/formlist.htm/ insurance forms and apps; and

WHEREAS, the standard health care enrollment form includes item C. Plan Option and instructs carriers to include information regarding pediatric dental coverage in this section; and

IT APPEARING, that specialty drugs include high cost drugs that require unique handling and/or patient education and which may be the only drugs to treat particular diseases, such as hemophilia and growth hormone deficiency; and

IT FURTHER APPEARING, that Freelancers placed all specialty drugs in its least preferred drug tier from January 1, 2014 to April 1, 2015; and

IT FURTHER APPEARING, that the placement of all specialty drugs in the least preferred drug tier means that no drugs were available for certain diseases in the most preferred tier contrary to N.J.A.C. 11:22-5.9(b)3; and

IT FURTHER APPEARING, that to correct this violation, Freelancers has voluntarily and temporarily moved all specialty drugs to Tier 1, eliminated Tier 4, revised the summary of benefits and coverage and policy form documents to eliminate Tier 4 cost sharing and reprocessed 145 specialty drug claims to pay at Tier 1 cost sharing, resulting in additional payments totaling \$136,367; and

IT FURTHER APPEARING, that Freelancers did not adjust the plan and benefits template used on federally facilitated marketplace to describe its change in cost sharing for

specialty drugs and incorrectly specified unapproved cost sharing for certain behavioral health and substance abuse services; and

IT FURTHER APPEARING, that Freelancers issued plans with \$75 copayments for outpatient mental health/substance abuse treatment and \$50 and \$75 copayments for therapeutic manipulation, which copayments did not satisfy the 50% test at N.J.A.C. 11:22-5.5(a); and

IT FURTHER APPEARING, that Freelancers has reduced the therapeutic manipulation copayment to \$35 and the outpatient mental health/substance abuse copayment to \$50 and has reprocessed 368 claims for outpatient mental health/substance abuse treatment and therapeutic manipulation, resulting in additional payments totaling \$6,990; and

IT FURTHER APPEARING, that Freelancers is revising the Summary of Benefits and Coverage, other marketing materials and the policy forms to specify the corrected copayment amounts; and

IT FURTHER APPEARING, that, from January to August 2015, Freelancers failed to issue individual health benefit plans contracts, small employer health benefit plan certificates to individual and groups covered under such plans that are compliant with the terms of the standard plans of the Individual Health Coverage ("IHC") and Small Employer Health ("SEH") programs and that accurately reflect the terms of the health benefit plans, contrary to N.J.S.A. 26:28-4, N.J.A.C. 11:24A-2.3 and N.J.A.C. 11:4-37.3(b)3; and

IT FURTHER APPEARING, that Freelancers has not provided the 96-hour supply of prescription drugs that require prior approval but for which prior approval had not been secured, as required by the IHC and SEH standard forms; and

IT FURTHER APPEARING, that Freelancers advises that the 96-hour supply of prescription drugs that require prior approval but for which prior approval has not been secured is being provided as of June 5, 2015; and

IT FURTHER APPEARING, that Freelancers has identified the members who may have been harmed by the failure to dispense a 96-hour supply and the scope of appropriate remediation, and has been working with the Department to effect that remediation; and

IT FURTHER APPEARING, that the nongroup enrollment form used by Freelancers does not include information regarding pediatric dental coverage in item C. or elsewhere on the form, that Freelancers advised the Department by letter dated July 31, 2015, that it would revise the nongroup enrollment form to capture information regarding pediatric dental coverage and submit the revised form to the Department prior to implementation, and that Freelancers submitted the revised form to the Department on August 28, 2015; and

IT FURTHER APPEARING, that Freelancers asserts that the violations set forth above were not intentional or intended to mislead the Department or the public; and

IF FURTHER APPEARING, that Freelancers has cooperated in the Department's investigation of these violations; and

IT FURTHER APPEARING, that this matter should be resolved upon the consent of the parties to these proceedings without resort to a formal hearing, and further good cause appearing;

NOW, THEREFORE, IT IS on the

day of September, 2015: ORDERED AND AGREED, that Freelancers will pay a fine in the amount of four hundred fifty thousand dollars (\$450,000) in four installments, with an initial payment of one hundred fifty thousand dollars (\$150,000) due on execution of this consent order by the company and with three subsequent payments of one hundred thousand dollars (\$100,000) each due on

October 15, November 15 and December 15, 2015. The payments shall be made through certified check, attorney trust account check, money order or electronic funds transfer made payment of "State of New Jersey – General Treasury"; and

IT IS FURTHER ORDERED AND AGREED, that the signed Consent Order together with the initial payment of \$150,000 shall be sent to Gale Simon, Assistant Commissioner, Department of Banking and Insurance, 20 West State Street, P. O. Box 329, Trenton, NJ 08625-0329; and

IT IS FURTHER ORDERED AND AGREED, that Freelancers will continue to institute measures and monitor operations in order to obtain and/or maintain compliance with all Department statutes and regulations; and

IT IS FURTHER ORDERED AND AGREED, that in the event full payment of the fine is not made in accordance with this Order, the Commissioner may exercise any and all remedies available by law, including but not limited to recovery of any unpaid penalties in summary proceedings, in accordance with the penalty enforcement law, N.J.S.A. 2A:58-10 et seq.; and

IT IS FURTHER ORDERED AND AGREED, that the provisions of this Consent Order represent a final agency decision and constitute a full and final resolution of the matters addressed herein.

Peter L. Hartt Director of Insurance Consented as to Form, Content and Entry:

Freelancers Consumer Operated and Oriented Program of New Jersey, Inc.
Name: Rescue Francick

Title:

Board Chair